University of Tennessee Health Science Center

UTHSC Digital Commons
Theses and Dissertations (ETD)

College of Graduate Health Sciences

12-2011

Characterization of the Mechanism of PPARγ-Mediated
PPAR -Mediated
Neointima Formation in Rodents
Ryoko Tsukahara
University of Tennessee Health Science Center

Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Amino Acids, Peptides, and Proteins Commons, Cardiovascular Diseases Commons, Lipids
Commons, and the Medical Sciences Commons

Recommended Citation
Tsukahara, Ryoko , "Characterization of the Mechanism of PPARγ-Mediated Neointima Formation in
Rodents" (2011). Theses and Dissertations (ETD). Paper 270. http://dx.doi.org/10.21007/
etd.cghs.2011.0324.

This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC
Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized
administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu.

Characterization of the Mechanism of PPARγ-Mediated
PPAR -Mediated Neointima Formation in
Rodents
Abstract
Lysophosphatidic acid (LPA) and its ether analog alkyl glycerophosphate (AGP) elicit arterial wall
remodeling when applied intralumenally into the uninjured carotid artery. LPA is the ligand of eight GPCRs
and the peroxisome proliferator-activated receptor γ (PPARγ). We pursued a gene knockout strategy to
identify the LPA receptor subtypes necessary for the neointimal response in a non-injury model of carotid
remodeling and also compared the effects of AGP and the PPARγ agonist rosiglitazone (ROSI) on balloon
injury-elicited neointima development. In the balloon injury model AGP significantly increased neointima;
however, rosiglitazone application attenuated it. AGP and ROSI were also applied intralumenally for 1 hour
without injury into the carotid arteries of LPA1, LPA2, LPA1&2 double knockout, and Mx1Cre-inducible
conditional PPARγ knockout mice targeted to vascular smooth muscle cells, macrophages, and
endothelial cells. The neointima was quantified and also stained for CD31, CD68, CD11b, and "-smooth
muscle actin markers. In LPA1, LPA2, LPA1&2 GPCR knockouts, Mx1Cre transgenic, PPARγ fl/- , and
uninduced Mx1Cre#PPAR! fl/- mice AGP- and ROSI-elicited neointima was indistinguishable in its
progression and cytological features from that of WT C57BL/6 mice. In PPARγ -/- knockout mice,
generated by activation of Mx1Cre-mediated recombination, AGP and ROSI failed to elicit neointima and
vascular wall remodeling. Our findings point to a difference in the effects of AGP and ROSI between the
balloon-injury- and the non-injury chemically-induced neointima. The present data provide genetic
evidence for the requirement of PPARγ in AGP- and ROSI-elicited neointimal thickening in the non-injury
model and reveal that the overwhelming majority of the cells in the neointimal layer express !-smooth
muscle actin.
Cyclic phosphatidic acid (1-acyl-2,3-cyclic-glycerophosphate, CPA), one of nature’s simplest
phospholipids, is found in cells from slime mold to humans and has largely unknown function. We find
that CPA is generated in mammalian cells in a stimulus coupled-manner by phospholipase D2 (PLD2), and
binds to and inhibits the nuclear hormone receptor PPAR! with nanomolar affinity and high specificity
through stabilizing its interaction with the corepressor SMRT. CPA production inhibits the PPAR! targetgene transcription that normally drives adipocytic differentiation of 3T3-L1 cells, lipid accumulation in
RAW264.7 cells and primary mouse macrophages, and arterial wall remodeling in vivo. Inhibition of PLD2
by shRNA, a dominant negative mutant, or a small molecule inhibitor blocks CPA production and relieves
PPARγ inhibition. We conclude that CPA is a novel second messenger and a physiological inhibitor of
PPARγ, revealing that PPARγ is regulated by endogenous agonists as well as by antagonists.
PPAR" is a nuclear hormone receptor related to many human diseases, including obesity, atherosclerosis,
diabetes, and cancers. Recent studies have provided evidence that LPA and its analog AGP activate
PPARγ. On the other hand, CPA, similar in structure to LPA, can be generated by PLD2 and negatively
regulates PPARγ functions. PPARγ agonists elicit lipid accumulation in macrophages and arterial wall
remodeling when topically applied to the carotid artery in the rat non-injury model. Stimulation of PLD2
protects the carotid artery from PPARγ-mediated neointima formation. Consistent with this, inhibition of
PLD2 activity using a PLD inhibitor, 5-fluoro-2-indolyl des-chlorohalopemide, diminishes the protective
effect of insulin. Stimulation of PPARγ by AGP leads to the recruitment of circulating vascular progenitor
cells into the vessel wall and the cells of the ensuing neointima express the α-smooth muscle actin
marker. We summarize our current knowledge about the mechanism of PPARγ elicits in response to the
endogenous lysophosphatidic acid analogs LPA, AGP, CPA, and the methodological challenges that one
faces when working on the intracellular action of LPA.
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ABSTRACT
Lysophosphatidic acid (LPA) and its ether analog alkyl glycerophosphate (AGP)
elicit arterial wall remodeling when applied intralumenally into the uninjured carotid
artery. LPA is the ligand of eight GPCRs and the peroxisome proliferator-activated
receptor ! (PPAR!). We pursued a gene knockout strategy to identify the LPA receptor
subtypes necessary for the neointimal response in a non-injury model of carotid
remodeling and also compared the effects of AGP and the PPAR! agonist rosiglitazone
(ROSI) on balloon injury-elicited neointima development. In the balloon injury model
AGP significantly increased neointima; however, rosiglitazone application attenuated it.
AGP and ROSI were also applied intralumenally for 1 hour without injury into the
carotid arteries of LPA1, LPA2, LPA1&2 double knockout, and Mx1Cre-inducible
conditional PPAR! knockout mice targeted to vascular smooth muscle cells,
macrophages, and endothelial cells. The neointima was quantified and also stained for
CD31, CD68, CD11b, and "-smooth muscle actin markers. In LPA1, LPA2, LPA1&2
GPCR knockouts, Mx1Cre transgenic, PPAR!fl/-, and uninduced Mx1Cre#PPAR!fl/- mice
AGP- and ROSI-elicited neointima was indistinguishable in its progression and
cytological features from that of WT C57BL/6 mice. In PPAR!-/- knockout mice,
generated by activation of Mx1Cre-mediated recombination, AGP and ROSI failed to
elicit neointima and vascular wall remodeling. Our findings point to a difference in the
effects of AGP and ROSI between the balloon-injury- and the non-injury
chemically-induced neointima. The present data provide genetic evidence for the
requirement of PPAR! in AGP- and ROSI-elicited neointimal thickening in the
non-injury model and reveal that the overwhelming majority of the cells in the neointimal
layer express !-smooth muscle actin.
Cyclic phosphatidic acid (1-acyl-2,3-cyclic-glycerophosphate, CPA), one of
nature’s simplest phospholipids, is found in cells from slime mold to humans and has
largely unknown function. We find that CPA is generated in mammalian cells in a
stimulus coupled-manner by phospholipase D2 (PLD2), and binds to and inhibits the
nuclear hormone receptor PPAR! with nanomolar affinity and high specificity through
stabilizing its interaction with the corepressor SMRT. CPA production inhibits the
PPAR! target-gene transcription that normally drives adipocytic differentiation of
3T3-L1 cells, lipid accumulation in RAW264.7 cells and primary mouse macrophages,
and arterial wall remodeling in vivo. Inhibition of PLD2 by shRNA, a dominant negative
mutant, or a small molecule inhibitor blocks CPA production and relieves PPAR!
inhibition. We conclude that CPA is a novel second messenger and a physiological
inhibitor of PPAR!, revealing that PPAR! is regulated by endogenous agonists as well as
by antagonists.
PPAR" is a nuclear hormone receptor related to many human diseases, including
obesity, atherosclerosis, diabetes, and cancers. Recent studies have provided evidence
that LPA and its analog AGP activate PPAR". On the other hand, CPA, similar in
structure to LPA, can be generated by PLD2 and negatively regulates PPAR" functions.
PPAR" agonists elicit lipid accumulation in macrophages and arterial wall remodeling
v

when topically applied to the carotid artery in the rat non-injury model. Stimulation of
PLD2 protects the carotid artery from PPAR"-mediated neointima formation. Consistent
with this, inhibition of PLD2 activity using a PLD inhibitor,
5-fluoro-2-indolyl des-chlorohalopemide, diminishes the protective effect of insulin.
Stimulation of PPAR" by AGP leads to the recruitment of circulating vascular progenitor
cells into the vessel wall and the cells of the ensuing neointima express the !-smooth
muscle actin marker. We summarize our current knowledge about the mechanism of
PPAR" elicits in response to the endogenous lysophosphatidic acid analogs LPA, AGP,
CPA, and the methodological challenges that one faces when working on the intracellular
action of LPA.
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CHAPTER 1.
1.1
1.1.1

GENERAL INTRODUCTION

LPA RECEPTORS AND SIGNALING

The Lysophosphatidic Acid Family

Lysophosphatidic acid (LPA) is a naturally occurring simple phospholipid that
functions as a bioactive lipid mediator and a second messenger. It is made up of a
glycerol backbone with a hydroxyl group, a phosphate group, and a long-chain saturated
or unsaturated fatty acid (Figure 1-1). Different molecular species of LPA, dominated by
16-, 18-, and 20-carbon chains, have been detected in biological fluids and elicit a wide
variety of biological actions including cell proliferation, migration, morphologic changes,
and survival.
Alkyl glycerophosphate (AGP; Figure 1-1) is an alkyl-ether analog of LPA. It is
abundant in brain tissue, found in egg yolk and saliva (Sugiura et al., 1999, Nakane et al.,
2001). AGP is a weak agonist of plasma membrane LPA receptors except the LPA5
receptor. LPA5 shows a preference for AGP relative to LPA (Williams et al., 2009).
Interestingly, AGP also shows a higher potency than LPA at the intracellular LPA
receptor peroxisome proliferator-activated receptor gamma (PPAR!) (Zhang et al., 2004,
Tsukahara et al., 2010).
Cyclic phosphatidic acid (CPA; Figure 1-1) is a naturally occurring acyl analog of
LPA present in mammalian blood and brain. CPA is also a weak agonist of many plasma
membrane LPA receptors (Fujiwara et al., 2005, Williams et al., 2009), whereas CPA is
an inhibitor of PPAR! (Tsukahara et al., 2010).
1.1.2

Plasma Membrane LPA Receptors and Signaling

LPA activates multiple plasma membrane receptors that belong to the G
protein-coupled receptor (GPCR) superfamily (Choi et al., 2010). LPA GPCRs have been
identified in two distinct gene families, the endothelial differentiation gene (EDG) family
and purinergic GPCR cluster. LPA1, LPA2, and LPA3 belong to the EDG family and
share 45-56% amino acid identity with the most divergence at the C-termini (Anliker and
Chun, 2004). LPA4 (P2Y9/GPR23), LPA5 (GPR92), LPA6 (P2Y5), GPR87, P2Y10, and
GPR35 are closely related to the P2Y purinergic receptor gene cluster (Ishii et al., 2009).
Upon LPA stimulation, LPA GPCRs interact with different G proteins (Gs, Gi/o, Gq and
G12/13) to activate various downstream pathways, which mediate the diverse cellular
effects of LPA.
LPA1 couples with three types of heterotrimeric G proteins: Gi/o, Gq, and G12/13
(Chun et al., 2010). LPA1 induces Ca2+ mobilization, cell proliferation, cell migration,
activation of mitogen-activated protein kinase (MAPK), and activation of Akt and Rho
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pathways (Anliker and Chun, 2004, Ishii et al., 2004). LPA1 is widely expressed in mice
and humans (Anliker and Chun, 2004, Choi et al., 2010). LPA1 deficient mice show
about 50% perinatal lethality within the first 3 weeks of age and the pups is attributed to
an impaired suckling behavior (Contos et al., 2000). Surviving LPA1 deficient mice have
a reduced body size and craniofacial dysmorphism with shorter snouts and more widely
spaced eyes (Contos et al., 2000).
LPA2 also interacts with Gi/o, Gq, and G12/13 (Chun et al., 2010). Hence, some of
the LPA2 signals are similar to LPA1, such as Ca2+ mobilization, proliferation, Akt
activation (Choi et al., 2010). LPA2 also signals via a C-terminal macromolecular
complex that includes proteins recruited to its PDZ-motif and LIM-motif (E et al., 2009).
LPA2 is highly expressed in the embryonic brain, testis, kidney, lung, and uterus in mice
(Choi et al., 2010). In humans it is detected in the testis, pancreas, prostate, thymus,
spleen, and leukocytes (Choi et al., 2010). LPA2 knockout mice are born normally and
show no obvious phenotypic abnormalities (Contos et al., 2002), whereas our group
showed these mice have increased sensitivity to radiation (Deng et al., 2007).
LPA3 can couple to Gi/o and Gq, and induces Ca2+ mobilization, phospholipase C
activation, and MAPK activation (Fukushima et al., 1998, Ishii et al., 2000). LPA3 is
highly expressed in testis, kidney, lung, small intestine, heart, thymus, brain, and in the
female reproductive system such as the oviduct, placenta, and uterus in adult mice (Choi
et al., 2010). It is also found in heart, pancreas, prostate, testis, lung, ovary, and brain in
humans (Choi et al., 2010). LPA3 deficient female mice show delayed and abnormal
embryo implantation in the uterus (Ye et al., 2005). LPA3 knockout along with the lack of
LPA1 and 2 also contribute to male infertility in aging mice (Ye et al., 2008).
LPA4 couples to Gi/o, Gq, and G12/13, as well as Gs, and induces Ca2+ mobilization,
cAMP accumulation, neurite retraction (Ishii et al., 2009). LPA4 is ubiquitously
expressed and specifically abundant in ovary, uterus, and placenta (Ishii et al., 2009).
LPA4 deficient mice display no apparent abnormalities (Lee et al., 2008), whereas an
independent study reported that LPA4 deletion in a different C57BL/6 background mouse
showed abnormal embryonic blood and lymphatic vessel formation (Sumida et al., 2010).
LPA5 couples to Gq and G12/13 (Kotarsky et al., 2006, Lee et al., 2006) and induces
Ca mobilization, neurite retraction, and cAMP accumulation (Ishii et al., 2009,
Williams et al., 2009). Unlike other LPA receptors LPA5 prefers AGP over LPA
(Williams et al., 2009) and is broadly expressed in tissues such as brain, small intestine,
placenta, spleen, lung, embryonic stem cells (Kotarsky et al., 2006, Lee et al., 2006).
2+

LPA6 couples to Gs and G12/13 (Yanagida et al., 2009). It was reported that
2-acyl-LPA rather than 1-acyl-LPA is more potent ligand of LPA6 (Yanagida et al.,
2009). LPA6 plays an important role in human hair growth (Pasternack et al., 2008,
Shinkuma et al., 2010).
GPR87 is highly expressed in squamous cell carcinomas and lung carcinomas
(Gugger et al., 2008). GPR87 was reported to increase Ca2+ mobilization using G16 fusion
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protein system (Tabata et al., 2007). P2Y10 fused with G16 can induce Ca2+ transients by
sphingosine-1-phosphate (S1P) as well as LPA (Murakami et al., 2008). The transcripts
of P2Y10 were detected in uterus, prostate, brain, lung, placenta, and skeletal muscle
(Murakami et al., 2008).
1.1.3

Intracellular LPA Receptor – PPAR!!

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear
hormone receptor superfamily, many of which function as lipid-activated transcription
factors (Tontonoz and Spiegelman, 2008). There are three PPAR isoforms that include
PPAR", $/%, and !. PPAR!, the most extensively studied among the three PPAR
subtypes, plays an important role in regulating lipid metabolism, glucose homeostasis,
cell differentiation, and motility (Duval et al., 2002, Evans, 2005, Kiec-Wilk et al., 2005).
PPAR! has two isoforms, PPAR!1 and !2. PPAR!2 differs from PPAR!1 only by 30
additional amino acids at the N-terminus, caused by differential promoter usage and
alternative splicing (Fajas et al., 1997). PPAR!1 is expressed in almost all tissues,
whereas PPAR!2 is highly expressed in only in the adipose tissue (Lehrke and Lazar,
2005). Genetic deletion of PPAR!1 causes embryonic mortality (Asami-Miyagishi et al.,
2004). In contrast, deletion of PPAR!2 causes minimal alterations in lipid metabolism
(Medina-Gomez et al., 2005). PPAR! heterodimerizes with the retinoid X receptor !
(RXR!), and it is the ligand binding domain (LBD) of PPAR! that interacts with its
agonists, including LPA (Weatherman et al., 1999). The PPAR"-RXR! heterodimer
binds the peroxisome proliferator response element (PPRE) in the promoter region of the
target genes. In the absence of ligands, the corepressors nuclear receptor corepressor
(NCoR) and silencing mediator of retinoid and thyroid hormone (SMRT) bind to the
heterodimer to suppress the target gene activation (Chen and Evans, 1995, Dowell et al.,
1999, Yu et al., 2005). Upon ligand binding, PPAR! undergoes a conformational change
that facilitates the dissociation of the corepressors and recruits coactivators such as p300
and PGC-1" (Nolte et al., 1998, Yu and Reddy, 2007), resulting in target gene
transcription (Lala et al., 1996).
A number of putative physiological agonists of PPAR! have been identified,
including 15d-prostaglandin J2 (15d-PGJ2) (Forman et al., 1995), oxidatively modified
fatty acids (Nagy et al., 1998, Baker et al., 2005, Li et al., 2008), select species of LPA
and AGP (McIntyre et al., 2003, Zhang et al., 2004, Tsukahara et al., 2006), oxidized
phospholipids (Davies et al., 2001), and nitrated fatty acids (Li et al., 2008). Among these
ligands, AGP stands out with an equilibrium binding constant of 60 nM (Tsukahara et al.,
2006) that is similar to that of the thiazolidinedione (TZD) class of synthetic agonists.
Interestingly, some of the residues required for PPAR! activation by AGP are different
from those required by ROSI. Histidine 323 and 449 within the ligand-binding domain of
PPAR! are required for the binding and activation by rosiglitazone (ROSI; Figure 1-1)
but are not required by AGP. Arginine 288 is an important residue for binding of AGP
but not ROSI. Tyrosine 273 is required for activation by both agonists (Tsukahara et al.,
2006).
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The TZD class of antidiabetics, ROSI, pioglitazone, and troglitazone, are full
agonists of PPAR! and have been clinically used to improve insulin sensitivity and lipid
metabolism in type 2 diabetics (Froberg and Andersen, 2005, Lautamaki et al., 2005,
Negro et al., 2005, Sarafidis et al., 2005). However, despite the beneficial effects of
PPAR! on glucose and lipid homeostasis, excessive PPAR! activity can be deleterious.
PPAR! agonists promote adipocytic differentiation of 3T3-L1 cells and also stimulate the
uptake of low density lipoprotein (LDL) by macrophages, leading to foam cell formation
in the arterial wall (Moore et al., 2001).
The cells of the vascular wall expresses LPA1-5 receptors as well as PPAR!
(Cheng et al., 2009). Topical application of unsaturated LPA species into the non-injured
carotid artery of rodents induces arterial wall remodeling (Yoshida et al., 2003), and this
response requires PPAR! but not LPA1 or LPA2 (Yoshida et al., 2003, Zhang et al., 2004,
Cheng et al., 2009) suggesting that LPA-mediated activation of PPAR! can also
contribute to vascular wall pathologies.
1.2

LPA IN VASCULAR BIOLOGY

Accumulating evidence has shown that LPA plays an important role in the
vascular system including proliferation, migration differentiation of vascular smooth
muscle cells (VSMCs) and vascular endothelial cells and the recruitment and trafficking
of macrophages and histiocytes (Figure 1-2).
LPA has been identified as a bioactive lipid and is produced in serum after the
activation of multiple biochemical pathways linked to platelet activation (Sano et al.,
2002, Spector, 2003, Tigyi and Parrill, 2003, Bolen et al., 2011). The concentration of
LPA in plasma is in the nanomolar range, whereas it can reach concentrations as high as
10 #M in serum during blood clotting (Baker et al., 2001, Aoki et al., 2002, Baker et al.,
2002). LPA production in blood requires autotaxin (ATX), which is a secreted
lysophospholipase D that generates LPA from lysophosphatidylcholine (LPC) (Tokumura
et al., 2002, Umezu-Goto et al., 2002).
Tokumura et al. reported that crude soybean lecithin contains a vasopressor lipid
identified as LPA (Tokumura et al., 1978a, Tokumura et al., 1978b). They demonstrated
LPA had hypertensive effects in rats and guinea pigs and hypotensive effects in cats and
rabbits (Tokumura et al., 1978b).
LPA increases endothelial permeability via RhoA activation (Schulze et al., 1997,
Alexander et al., 1998, van Nieuw Amerongen et al., 2000). LPA activates the
endothelial isoform of nitric oxide synthase (eNOS) through the activation of the
PI3-K/Akt pathway (Kou et al., 2002). LPA also induces E-selectin, vascular cell
adhesion molecule-1 (VCAM-1), and vascular endothelial growth factor-C (VEGF-C)
expression in human endothelial cells (Rizza et al., 1999, Lin et al., 2008). Moreover,
LPA regulates the expression of pro-atherogenic connective tissue growth factor (CTGF)
in human endothelial cells (Muehlich et al., 2004). CTGF is known to mediate migration
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Figure 1-2

The effects of LPA in the vasculature
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of monocytes, VSMCs, and activated platelets.
LPA promotes proliferation and migration of VSMCs (Hayashi et al., 2001, Siess,
2002, Kim et al., 2006). Hayashi et al. showed that LPA promotes VSMC
dedifferentiation from the contractile phenotype to a secretory phenotype and stimulates
VSMC signaling pathways in vitro (Hayashi et al., 2001). LPA induces early growth
response gene 1(Egr-1), an important transcription factor that activates expression of a set
of genes involved in vascular diseases (Cui et al., 2006). Myocyte contractility is
regulated by LPA via Gi-mediated mechanism (Cremers et al., 2003). The authors
showed that LPA suppressed isoprenaline-induced cell shortening through the activation
of LPA1 and/or LPA3 in a pertussis toxin sensitive manner.
LPA activates monocytes with low nanomolar concentration (Fueller et al., 2003)
and recruits them via inducing monocyte chemoattractant protein-1 (MCP-1) secretion
through p38 and JNK pathways in endothelial cells (Lin et al., 2006, Shimada and
Rajagopalan, 2010) suggesting the important role in inflammation processes. LPA
inhibits conversion of monocytes into migratory cells and keep them in the
subendothelium (Llodra et al., 2004). LPA via LPA1 and LPA3 induces CXCL-1, which
promotes monocyte adhesion to the murine vascular endothelium (Zhou et al., 2011).
Many of the cellular responses elicited by LPA, including platelet activation
(Siess et al., 1999, Rother et al., 2003, Haseruck et al., 2004), endothelial cell activation
(Siess et al., 1999), proliferation, migration, and phenotypic modulation of VSMCs
(Hayashi et al., 2001, Siess, 2002, Kim et al., 2006), can be involved in neointima
formation. Oxidative modification of LDL is considered to be an early event in arterial
wall remodeling leading to atherosclerosis (Stocker and Keaney, 2004, Asmis et al.,
2005); and uptake and oxidation of LDL in the arterial wall is an important mechanism in
the pathogenesis of atherosclerosis (Meydani, 2001). It has been shown that LPA is
formed during mild oxidation of LDL (mox-LDL) (Siess et al., 1999, Law et al., 2000).
In addition, the lipid-rich core of human atherosclerotic plaques, which accumulates
oxidized lipids including mox-LDL, contains several species of LPA and AGP (Siess et
al., 1999). LPA and AGP accumulated in human atherosclerotic plaques are likely to
activate platelets and initiate thrombus formation upon plaque rupture (Rother et al.,
2003, Spector, 2003). Following plaque rupture, LPA becomes available to circulating
platelets, initiating activation, which in turn may contribute to the induction of
thrombosis, leading to myocardial infarction and stroke. Furthermore, a recent report
revealed that ATX can bind to platelet integrin receptors through its N-terminal
somatomedin B-kike domains (Hausmann et al., 2011) suggesting the possibility that
ATX could be localized to the surface of activated platelets, which might concentrate the
production of LPA at the sites of vascular injury.
Some clinical studies have shown the correlation between plasma LPA and
vascular diseases. Chen et al showed that the serum LPA level was significantly elevated
in patients with acute myocardial infarction (Chen et al., 2003).
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LPA also plays an important role in vascular development (van Meeteren et al.,
2006). ATX-deficient mice die at approximately embryonic day 9.5 with severe vascular
formation defects in the yolk sac and enlarged embryonic blood vessels (Tanaka et al.,
2006, van Meeteren et al., 2006). Mice that overexpress ATX have elevated plasma LPA
levels and show bleeding diathesis, whereas ATX+/- heterozygous mice have almost half
the plasma LPA levels and are prone to thrombosis (Pamuklar et al., 2009).
1.3
1.3.1

VASCULAR WALL REMODELING

Neointima Formation Induced by LPA

Neointimal lesions are characterized by accumulation of cells within the arterial
wall and are an early step in the pathogenesis of atherosclerosis (Ross, 1999, Baim et al.,
2002). Atherosclerosis is the leading cause of death and serious morbidity in the United
States (Xu et al., 2010).
Yoshida et al. reported that LPA species containing unsaturated fatty acyl groups
16:1, 18:1, and 18:2 induced neointima formation when injected intralumenally into the
rat carotid artery, whereas saturated 16:0 and 18:0 LPA species were inactive (Yoshida et
al., 2003). This model comes close to the pathophysiological response seen in humans
because mechanical injury is not the cause of the arterial wall remodeling leading to
neointimal lesions. In Yoshida's model, LPA was injected through the external carotid
artery into a ligated section of the common carotid artery (CCA) that was rinsed free of
blood and maintained close to the mean arterial perfusion pressure. There was no
mechanical injury or removal of endothelial cells in the CCA. A brief one-hour exposure
to unsaturated but not to saturated species of LPA caused neointima development.
Our group found that the LPA-elicited neointima was not mediated by the LPA
GPCRs LPA1 and LPA2, which are the major LPA receptor subtypes expressed in the
vessel wall (Cheng et al., 2009). PPAR"-specific inhibitor, GW9662, abolished the
LPA-induced neointima formation, suggesting that arterial wall remodeling elicited by
LPA is a PPAR"-mediated response (Zhang et al., 2004). Conversely, the
PPAR"-specific agonist ROSI also elicited neointima formation in the same model.
Genetic evidence also supports the role of PPAR" in arterial wall remodeling. When
conditional knockout PPAR!-/- mice with this receptor knocked out in the endothelial
cells, VSMCs, and cells of the macrophage/monocyte lineage were exposed to AGP,
LPA, or ROSI no neointima formation or vascular wall remodeling was observed (Cheng
et al., 2009).
It is important to note that in a carotid injury model, ROSI diminished the size of
the neointima. The opposite effect of ROSI and LPA in these two different models
indicates differences in the mechanism underlying vascular wall remodeling in these
models (Cheng et al., 2009). These results, combined with the observation that GW9662
abolished neointima in response to ROSI or AGP (Zhang et al., 2004), suggest that
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PPAR! is required for LPA-induced neointima formation in the absence of vascular wall
injury.
Panchatcharam et al. reported that LPA1 and LPA2 receptors play an important
role in injury-induced neointima formation (Panchatcharam et al., 2008). They
demonstrated that neointima formation induced by mechanical injury was attenuated in
LPA1-/-LPA2-/- mice compared to wild type mice. In contrast, in our non-injury model,
LPA1-/-LPA2-/- mice developed neointima in response to LPA treatment (Cheng et al.,
2009), suggesting that the mechanism underlying these two models in neointima is
fundamentally different.
Moreover, Subramanian et al. reported that LPA1 and LPA3 GPCRs play an
important role in injury-induced neointima formation (Subramanian et al., 2010). Using a
wire-injury model, these authors showed that neointima formation was inhibited by the
LPA1 and LPA3 inhibitor Ki16425 and that vascular wall remodeling induced by LPA
was inhibited by short-term knockdown of either LPA1 or LPA3 with small interfering
RNA (siRNA) (Subramanian et al., 2010). In sharp contrast with the findings of
Subramanian et al., LPA1-/- mice in our non-injury model develop neointima in response
to AGP stimulation. Moreover, although LPA1 and LPA3 GPCRs are respectively 12 and
100 times less sensitive to AGP than LPA (Fujiwara et al., 2005), AGP is more potent
than LPA in inducing neointima formation (Zhang et al., 2004). Subramanian and
colleagues also observed that Mac-2 positive cells accumulated in the neointimal area
after vascular injury (Subramanian et al., 2010); in contrast, our non-injury model
showed few macrophages in the neointimal region induced by AGP or ROSI (Cheng et
al., 2009), suggesting that the cellular elements leading to neointima formation are
different between the two models.
Although some clinical studies in diabetic patients have shown a reduction in
carotid artery wall thickness after treatment with TZDs (Minamikawa et al., 1998,
Haffner et al., 2002), other studies suggested that ROSI increases the risk of myocardial
infarction and death from cardiovascular causes (Goldberg et al., 2005, Nissen and
Wolski, 2007, 2010), indicating that TZD therapy may actually increase the risk of
cardiovascular events. Moreover, in 2010, the U.S. Food and Drug Administration
restricted use of ROSI to patients with type 2 diabetes due to the potential for
cardiovascular ischemic risks, including heart attack.
1.3.2

The Structure-Activity Relationship (SAR) of Neointima Induction

The different molecular species of LPA contain either saturated or unsaturated
fatty acids. Only unsaturated LPA species including oleoyl (18:1), linolenoyl (18:2), and
arachidonoyl (20:4) LPA induce neointima (Yoshida et al., 2003, Zhang et al., 2004). In
contrast, saturated LPA species including palmitoyl (16:0) and stearoyl (18:0) LPA are
inactive in non-injury carotid wall remodeling assay (Yoshida et al., 2003, Zhang et al.,
2004). The SAR of neointima induction does not match that of the known LPA GPCRs
because saturated LPA activate LPA GPCRs (Zhang et al., 2004). On the other hand,
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experiments conducted to determine the SAR for PPAR! activation in vitro and the SAR
of the neointimal response in vivo are closely matched (Zhang et al., 2004). In vitro,
ROSI, unsaturated LPA and AGP species all activate the peroxisome activator response
element-containing acyl-coenzyme A oxidase-luciferase (PPRE-Acox-Luc) reporter
construct, whereas all saturated LPA species, CPA, and the related lipid mediator S1P are
inactive (Zhang et al., 2004). The similarity of the SAR of neointimal lesions and PPAR!
activation support the hypothesis that LPA receptor required for neointima formation is
PPAR! (Zhang et al., 2004, Tsukahara et al., 2006).
1.4
1.4.1

THE ROLE OF PPAR!!

PPAR!! in Vascular Biology

PPAR! plays an important role in the cardiovascular system. PPAR! is expressed
in all cell types of the vessel wall (Marx et al., 1998, Delerive et al., 1999, Rangwala and
Lazar, 2004), as well as in monocytes and macrophages (Tontonoz et al., 1998). PPAR!
expression is upregulated in VSMCs (Law et al., 2000), endothelial cells (Delerive et al.,
1999), and macrophages (Tontonoz et al., 1998) in human atherosclerotic plaques and
neointimal lesions.
PPAR! expression is also elevated in neointimal lesions after mechanical injury to
the endothelium (Law et al., 2000). There are some reports that ROSI suppresses
neointima formation after endothelial injury in rodent (Lim et al., 2006, Meredith et al.,
2009). Our group found that when AGP was infused to an injured carotid artery,
neointima was augmented, although ROSI attenuated neointima induced by mechanical
injury (Cheng et al., 2009). Furthermore, in our non-injury model, ROSI induces
neointima when applied intralumenally into the carotid artery (Zhang et al., 2004, Cheng
et al., 2009). Thus, the mechanisms underlying neointima formation in the
chemically-induced neointima model are likely to be different from those in the
injury-induced neointima models. It is important to note that circulating LPA makes a
complex with serum albumin (Tigyi and Miledi, 1992) and LPA-albumin complex cannot
activate PPAR! because the LPAcomplex can not be internalized (Zhang et al., 2004).
Therefore, the source of LPA is likely to originate from either the uptake lipid particles
such as oxidized LDL (oxLDL) or generated intracellularly.
1.4.2

PPAR!! in Macrophages/Monocytes

Macrophages play essential roles in immunity and lipid homeostasis. It has been
reported that PPAR! is induced during the differentiation of monocytes into macrophages
and is highly expressed in activated macrophages including the foam cells in
atherosclerotic lesions (Ricote et al., 1998, Tontonoz et al., 1998). PPAR! is also induced
during the differentiation of monocytes into dendritic cells (Figure 1-3) (Gosset et al.,
2001, Szatmari et al., 2004).
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Figure 1-3

Mechanism of PPAR!! -mediated effects
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CD36 is a scavenger receptor and one of the PPAR! response genes. PPAR!
activation upregulates CD36 expression, which results in increased lipid uptake in
macrophages (Figure 1-3) (Tontonoz et al., 1998). In macrophages, oxLDL uptake
through CD36 results in the development of foam cells. Accumulation of foam cells in
the arterial wall is a hallmark of the early atherosclerotic lesion. There is evidence that
oxLDL uptake is decreased in PPAR! deficient macrophages due to the loss of CD36
(Moore et al., 2001) suggesting that the activation of PPAR! in macrophages plays an
important role atherosclerosis.
Interestingly, it has been shown that macrophages are accumulated in the
injury-induced neointima lesions (Subramanian et al., 2010). On the other hand, very few
macrophages are detected in neointima lesions induced in non-injury model (Cheng et al.,
2009) implying that the roles of macrophages in the two models are different.
Dendritic cells are antigen-presenting cells, which play an important role in
stimulating T and B cells. It has been shown that PPAR! promotes antigen-presenting
molecule CD1d expression in DCs, and LPA is capable of modulating CD1d expression
(Szatmari et al., 2004, Leslie et al., 2008). This line of evidence suggests that LPA may
have a critical role in dendritic function through the activation of PPAR!.
1.4.3

PPAR!! in Lipid Metabolism

Excess fat is stored as triglycerides in the adipose tissue, and fatty acids are
released into the circulation in response to increased energy requirement. If lipid storage
capacity of adipocytes is exceeded, adipocytes can no longer regulate the level of free
fatty acids (FFAs) in the circulation, which results in the inappropriate deposition of
lipids in tissues, including the liver and skeletal muscle (Camp et al., 2002).
Accumulation of triglycerides in the liver and the muscle is thought to lead to metabolic
dysregulation, especially,to increased levels of triglycerides and FFAs (Camp et al.,
2002).
It has been shown that PPAR! plays an important role in regulating glucose
metabolism and fatty acid storage (Evans, 2005). Activation of PPAR! in adipose tissue
leads to target gene expression including aP2, CD36, PEPCK, which are involved in FFA
uptake and triglyceride storage (Rosen and MacDougald, 2006). Consistent with their
ability to promote lipid uptake and storage in cultured cells, PPAR! agonists increase
adipose tissue mass in vivo (Tai et al., 1996).
LPA can be generated intracellularly through multiple pathways and is also an
intermediate of fatty acid metabolism. Fatty acids taken up by cells are activated to form
fatty acyl-coenzyme A (fatty acyl-CoA). The next biochemical step is the generation of
LPA from fatty acyl-CoA and glycerol-3-phosphate by the different forms of
glycerophosphate acyltransferase (GPAT; Figure1-3) (Vancura et al., 1991). The LPA
generated by GPAT might activate PPAR! leading to upregulation of PPAR! target genes
involved in lipogenesis, lipid storage, and adipocyte differentiation (Stapleton et al.,
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2011). In addition, CPA, an acyl analog of LPA, is also generated intracellularly by
phospholipase D 2 (PLD2) upon the stimulation of insulin, and negatively regulates
PPAR! functions (Tsukahara et al., 2010) suggesting that PPAR! functions are regulated
by agonists as well as by antagonists.
1.5
1.5.1

CYCLIC PHOSPHATIDIC ACID

CPA Production

CPA (Figure 1-1), an analog of LPA with a five-atom ring linking the phosphate
to two of the glycerol carbons, is found in diverse organisms from slime mold to humans
(Murakami-Murofushi et al., 2000); its functions are largely unknown. The concentration
of CPA in human serum is estimated to be ~0.01 #M, 10-fold lower than that of LPA
(Eichholtz et al., 1993, Kobayashi et al., 1999).
Friedman et al. demonstrated that CPA can be formed by a intermediate product
through transphosphatidylation reaction with lysophosphatidylcholine (LPC) mediated by
a bacterial PLD (Friedman et al., 1996). LPC is a second most abundant phospholipid in
serum and a substrate of PLD (Tokumura et al., 1983). Tsuda et al. found that fetal
bovine serum has activity to produce CPA, and they identified ATX, a serum
lysophospholipase D (lysoPLD), that can produce CPA ex vivo in an ether/water two
phase buffer system (Tsuda et al., 2006). ATX may not be the only source responsible of
CPA in serum. In addition, our group showed that CPA is generated intracellularly from
LPC through the activation of PLD2 (Tsukahara et al., 2010).
1.5.2

CPA Receptors

It has been reported that CPA activates LPA1-5 and GPR87 receptors (Fujiwara et
al., 2005, Baker et al., 2006, Williams et al., 2009, Tigyi, 2010). CPA activates LPA1-4
receptors with a lower potency than that of LPA (Fujiwara et al., 2005, Baker et al.,
2006), whereas CPA activates LPA5 with a slightly higher EC50 concentration than LPA
(Williams et al., 2009). GPR87 and P2Y10 are also activated by CPA with lower
efficiency than LPA (Tigyi, 2010). In contrast to LPA, CPA does not activate
intracellular LPA receptor PPAR! (Zhang et al., 2004, Tsukahara et al., 2010).
1.5.3

Functions of CPA

The concentration of CPA in human serum is estimated to be ~0.01 #M, 10-fold
lower than that of LPA (Eichholtz et al., 1993, Kobayashi et al., 1999). Although CPA is
structurally similar to LPA and activates LPA GPCRs (Fujiwara et al., 2003, Fujiwara et
al., 2005, Williams et al., 2009), CPA shows several unique actions compared to LPA.
CPA inhibits cell proliferation in human fibroblast cells whereas LPA stimulates it
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(Fischer et al., 1998). CPA directly inhibits Cdc25, leading to dephosphorylation
of cyclin-dependent kinase 2 that results in cell cycle arrest (Murakami-Murofushi et al.,
2002). Nanomolar concentrations of CPA promote neuron outgrowth and enhance
differentiation and survival in cultured embryonic hippocampal neurons (Fujiwara et al.,
2003). CPA with an acyl chain inhibits LPA-induced platelet aggregation, whereas CPA
with an alkyl chain shows weak platelet aggregation (Gueguen et al., 1999). Although
LPA induces transcellular migration, CPA shows inhibitory effect on transcellular
migration in rat hepatoma, human lung cancer, and mouse melanoma cells (Mukai et al.,
1999). It has been reported that CPA attenuates cancer cell invasion in vivo (Ishihara et
al., 2004, Uchiyama et al., 2007). Moreover, metabolically stabilized derivatives of CPA
suppressed pulmonary metastasis when mouse melanoma cells were injected into
C57BL6 mice (Baker et al., 2006).
1.6
1.6.1

PHOSPHOLIPASE D

Functions of PLD

PLD catalyzes the hydrolysis of phosphatidylcholine (PC) and LPC to generate
the lipid second messenger phosphatidic acid (PA) or CPA and choline (Frohman et al.,
1999). PLD can also catalyze the hydrolysis of LPC to generate LPA, which could be the
source of ligand for intracellular LPA receptors. PLD is conserved in cells from bacteria
to mammals (Exton, 2002). Mammalian PLD is regulated by many factors, including
phosphatidylinositol-4,5-bisphosphate (PIP2), protein kinase C (PKC), and small
G-proteins of the Rho, Ral, and ARF families (Liscovitch et al., 2000, Exton, 2002). PLD
plays an important role in a wide variety of cellular responses such as vesicular
trafficking (Cockcroft, 1996, Liscovitch, 1996), Golgi function (Yang et al., 2008,
Riebeling et al., 2009), cell proliferation, migration, and survival (Plevin et al., 1991,
Banno et al., 2001, Zheng et al., 2006, Carrigan et al., 2007).
1.6.2

Mammalian PLD Isoforms

There are two mammalian PLD isoforms, PLD1 and PLD2 (Liscovitch et al.,
2000). These isoforms share about 50% amino acid similarity and have a highly
conserved HKD domain necessary for catalysis. They also require PIP2 as a cofactor for
activation, however, they exhibit quite distinct regulatory properties (Liscovitch et al.,
2000). PLD1 has a low basal activity and responds to members of small G proteins Rho
and ARF, whereas PLD2 shows a high basal activity and a little or no response to PLD1
activators (Colley et al., 1997, Exton, 2002). Their distribution is also different. PLD1 is
predominantly expressed in Golgi, lysosome, and perinuclear endosome, whereas PLD2
is exclusively expressed at the plasma membrane (Brown et al., 1998, Du et al., 2004).
Our recent study showed that PLD2, but not PLD1, can generate CPA from LPC
intracellularly in mammalian cells (Tsukahara et al., 2010). Furthermore, we showed that
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inhibition of PLD2 by knockdown or dominant negative constructs blocked the protective
effect of insulin or other stimulators of this enzyme (Tsukahara et al., 2010).
1.6.3

PLD Inhibitors

Primary alcohols are often used to quench PLD activity in vitro studies to confirm
PLD effects. PLD catalyses a transphosphatidylation reaction in the presence of primary
alcohols like primary butanol, leading to the formation of phosphatidylethanol instead of
PA (Munnik et al., 1995). Therefore, primary alcohols inhibit cellular responses elicited
by PLD1- and PLD2-produced PA. Secondary and tertiary alcohols cannot be substrates
of the transphosphatidylation reaction. 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) is
an analog of halopemide, a dopamine receptor antagonist, and identified as an inhibitor of
both PLD1 and PLD2 (Monovich et al., 2007, Su et al., 2009). FIPI inhibits
PLD-mediated PA production, leading to the inhibition of F-actin cytoskeleton
reorganization, cell spreading, and chemotaxis (Su et al., 2009). Recently, we
demonstrated that FIPI inhibits PLD2-mediated CPA production in human peripheral
mononuclear cells (Tsukahara et al., 2010).

15

CHAPTER 2. LYSOPHOSPHATIDIC ACID-INDUCED ARTERIAL WALL
REMODELING: REQUIREMENT OF PPAR! BUT NOT LPA1 OR LPA2 GPCR*
2.1

INTRODUCTION

Lysophosphatidic acid (LPA, 1-acyl-2-hydroxy-sn-glycero-3-phophate) and its
ether-linked analog alkyl glycerophosphate (AGP,
1-alkyl-2-hydroxy-sn-glycero-3-phophate) are naturally occurring lipid mediators with
growth factor-like effects in almost every mammalian cell type (Siess and Tigyi, 2004).
AGP and LPA elicit their biological responses through eight plasma membrane receptors
that belong to the GPCR superfamily and intracellularly through the peroxisome
proliferator-activated receptor ! (PPAR!) (McIntyre et al., 2003, Tsukahara et al., 2006).
AGP and LPA are present in blood plasma (Xiao et al., 2001) and become enriched after
minimal oxidative modification of LDL (Rother et al., 2003, Zhang et al., 2004). The
lipid rich core in human carotid endarterectomy specimens contains high concentrations
of AGP and LPA (Siess et al., 1999) and upon plaque rupture could activate platelet
aggregation and lead to atherothrombosis (Rother et al., 2003).
All major cell types of the arterial wall respond to LPA. In endothelial cells, LPA
has been shown to regulate the expression of adhesion molecules, proliferation,
apoptosis, permeability, motility and cell-to-cell contacts responsible for transendothelial
permeability (Rizza et al., 1999, Lin et al., 2006). LPA induces vascular smooth muscle
cell (VSMC) contraction, proliferation (Tokumura et al., 1994) and phenotypic
transdifferentiation in vitro (Hayashi et al., 2001, Zhang et al., 2004). LPA and oxidized
LDL inhibit macrophage/dendritic cell egress across endothelial cell monolayers (Angeli
et al., 2004, Llodra et al., 2004). LPA also stimulates the formation of platelet-monocyte
aggregates, which are considered as an early marker of acute myocardial infarction
(Fueller et al., 2003, Siess, 2006).
Yoshida and colleagues were the first to test lumenally applied LPA on the
non-injured arterial wall in vivo (Yoshida et al., 2003). These authors infused LPA
through the external carotid artery of rats into a ligated section of the common/internal
carotid artery that was rinsed free of blood and maintained close to the mean arterial
perfusion pressure. In this model, which involves no mechanical injury or the removal of
endothelial cells in the common carotid artery, after 1-hour exposure to unsatured but not
to saturated species of low micromolar LPA leads to neointima development. These
authors interpreted their observation as if a yet unknown LPA GPCR activated only by
unsaturated species of LPA. However, the structure-activity relationship of neointima
induction does not match that of the known LPA GPCRs but matches the
structure-activity relationship of PPAR! activation by LPA.
* Adapted with permission. Cheng Y, Makarova N, Tsukahara R, Guo H, Shuyu E,
Farrar P, Balazs L, Zhang C, Tigyi G (2009) Lysophosphatidic acid-induced arterial
wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. Cell Signal
21:1874-1884.
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LPA is an agonist of the nuclear transcription factor PPAR! (McIntyre et al.,
2003). PPAR! has long been implicated in atherogenesis (Diep and Schiffrin, 2001, Li
and Glass, 2002). Many compounds activate PPAR, including the synthetic drug
Rosiglitazone (ROSI) of the thiazolidinedione family, oxidized phospholipids, fatty acids,
eicosanoids, and oxidized LDL. PPAR! is expressed in macrophages/monocytes,
vascular smooth muscle cells, endothelial cells, and is highly expressed in atherosclerotic
lesions and hypertensive vascular wall (Diep and Schiffrin, 2001). GW9662, a specific
irreversible antagonist of PPAR! (Leesnitzer et al., 2002) completely abolished AGP,
LPA and ROSI-induced neointima formation in the rat model (Zhang et al., 2004).
Although, these lines of evidence support the role of PPAR! as the receptor responsible
for the neointimal thickening elicited by AGP and LPA, the pharmacological evidence
does not exclude the possibility that LPA GPCR mediate this response alone or through
the indirect activation of PPAR!. Several investigators reported that systemic and chronic
administration of ROSI attenuates neointima in models with mechanical injury of the
arterial wall which is different from findings reported using the non-injury model (Lim et
al., 2006, Lee et al., 2009).
Here we compared the effects of AGP and ROSI on arterial wall remodeling in a
balloon injury model with that in the non-injury model and found that these agents elicit
model-dependent different responses. We pursued a gene knockout (KO)-based strategy
to seek the identification of the LPA receptor subtype(s) necessary for the neointimal
response in the non-injury model. We tested AGP and ROSI in LPA1, LPA2, LPA1 and
LPA2 double knockout (DKO), and in inducible conditional PPAR! knockout mice
targeted to VSMCs, macrophages and endothelial cells by the Mx1Cre promoter. We also
sought to characterize the phenotypic properties of cells involved in LPA-elicited
neointimal thickening and found that the overwhelming majority of the cells in the
neointimal layer express !SMA characteristic of the VSMC lineage. Our findings showed
that LPA1&2 GPCR KO mice behave like wild type (WT) mice whereas, PPAR! KO fail
to develop AGP- and ROSI-induced neointimal thickening.
2.2
2.2.1

EXPERIMENTAL PROCEDURES

Reagents

1-O-octadecenyl glycerophosphate (AGP 18:1) was purchased from Avanti Polar
Lipids (Alabaster, AL). Rosiglitazone (ROSI) was from ALEXIS Biochemicals, Inc.
(Plymouth Meeting, PA). TRIzol Reagent, DNase I, and the ThermoScript RT-PCR
System for First-Strand cDNA Synthesis were from Invitrogen (Carlsbad, CA). The RT2
Real-Time SYBR Green/ROX kit was purchased from SuperArray (Frederick, MD).
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2.2.2

Quantitative RT-PCR

Total RNA was prepared using TRIzol reagent from mouse common carotid
artery from which the adventitia had been peeled off. One #g of total RNA was digested
with DNase I and used for the subsequent synthesis of cDNA using the First Strand
Synthesis kit as recommended by the manufacturer. The following primer pairs were
used: LPA1, (forward) GTCTTCTGGGCCATTTTCAA and (reverse) TCATAGTCCTC
TGGCGAACA; LPA2, (forward) GGGCCAGTGCTACTACAACG and (reverse) ACC
AGCAGATTGGTCAGCA; LPA3, (forward) GAATTGCCTCTGCAACATCTC and
(reverse) ATGAAGAAGGCCAGGAGGTT; LPA4, (forward) TCTGGATCCTAGTCCT
CAGTGG and (reverse) CCAGACACGTTTGGAGAAGC; LPA5, (forward) CGCCATC
TTCCAGATGAAC and (reverse) TAGCGGTCCACGTTGATG; and GAPDH,
(forward) CTGCACCACCAACTGCTTAG and (reverse) GGGCCATCCACAGTCTTC
T. The primer sets were designed with a melting temperature of 59–61°C. Amplicon size
was 50–200 bases. Amplification was performed for 40 cycles at 94ºC/15 sec and 60ºC
/60 sec. Quantitative values were obtained from the threshold cycle value (Ct) as
previously described (Guo et al., 2008).
2.2.3

Immunofluorescence Staining

Cryosections dipped in 4% buffered paraformaldehyde were blocked in 10% goat
serum and incubated with rat anti-mouse CD31 (anti-PECAM-1 rat monoclonal antibody,
1:400 dilution; RDI Inc.; Concord, MA), or anti-mouse CD11b (anti-Mac-1 rat
monoclonal antibody, 1:100 dilution; BD Pharmingen; San Diego, CA), or anti-mouse
CD68 (anti-macrosialin rat monoclonal antibody, 1:400 dilution; ABD SeroTec; Oxford,
UK) antibodies. Anti-rat fluorescein-conjugated secondary antibody was used at a 1:200
dilution (Vector Laboratories; Burlingame, CA). Cell nuclei were stained with DAPI. The
MOM kit (Vector Laboratories) was used for !-smooth muscle actin (!SMA) staining.
Briefly, after fixation and permeabilization, tissue sections were incubated with mouse
IgG blocking reagent for 1 h, followed by 1:200 diluted anti-!SMA antibody (1:400
dilution; DAKO; Carpinteria, CA) and then 1:200 diluted Texas Red conjugated
anti-mouse antibody (1:200 dilution; Vector Laboratories). For the double staining of
mouse carotid artery sections, !SMA staining was carried out using the MOM kit on
anti-CD11b- or anti-CD68-stained sections. The fluorescence was observed by Nikon
Eclipse 80i fluorescence microscope. Merged images for double-stained sections were
generated by the NIS-Elements (V2.1, Nikon Instruments) image analysis software.
2.2.4

Rat Carotid Artery Balloon Injury Model

The animal procedures were approved by the Institutional Animal Care and Use
Committee at the University of Tennessee and were consistent with the Guide for the
Care and Use of Laboratory Animals (National Institutes of Health publication 85-23,
revised 1985). Carotid artery balloon injury was induced in male Sprague-Dawley rats
(230 to 300 g) anesthetized with ketamine (80 mg/kg) and xylazine (5 mg/kg). Under a
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dissecting microscope, the right common carotid artery was exposed through a midline
cervical incision. A 2F Fogarty catheter (Baxter-Edwards) was introduced via an
arteriotomy via the external carotid artery, and then the catheter was advanced to the
proximal edge of the omohyoid muscle. The balloon was inflated with saline and
withdrawn three times from under the proximal edge of the omohyoid muscle to the
carotid bifurcation. The common and internal carotid arteries were clamped and a 100 #l
aliquot of AGP (10 µM), ROSI (10 µM), or vehicle was instilled into the injured segment
via a PE-10 catheter and was incubated for 60 min. Subsequently, the catheter was
withdrawn and the external carotid artery was ligated with 6-0 silk suture. The clips at the
common and internal carotid arteries were released, and blood flow in the common
carotid artery was restored. Three weeks after injury the carotids were dissected and
processed for histology as described for the mouse specimens above. Each group
consisted of six rats.
2.2.5

Transgenic and Knockout Animals

LPA1 and LPA2 knockout breeders on C57BL/6 background were generously
provided by Jerold Chun (Scripps Institute, CA) and have been characterized previously
(Contos et al., 2000, Contos et al., 2002, Yang et al., 2002). LPA1&2 double knockout
(DKO) mice were obtained by crossing homozygous LPA1 males with LPA2 females.
Genotyping of the DKO mice was done as described by Contos et al. coworkers (Contos
et al., 2002). The C57BL/6-Mx1Cre mouse line was made available by Dr. Matthew
Breyer (Vanderbilt University) that allows the differential, interferon (IFN)-inducible
targeting of the Cre recombinase to vascular and renal endothelium, vascular smooth
muscle cells and macrophages (Akiyama et al., 2002, Schneider et al., 2003). The
Mx1Cre is induced intraperitoneal injection of the IFN-inducer synthetic double-stranded
RNA polyinosinic-polycitidylic acid (pIpC, Sigma-Aldrich, St. Louis, MO). Dr. Mark
Magnuson (Vanderbilt University) generously provided us a mouse line with exon 2 of
PPAR! has been flanked by LoxP sites on the C57BL/6 background (Jones et al., 2002).
PPAR!fl/- mice were bred with homozygous Mx1Cre mice to generate mice that are
PPAR!fl/-#Mx1Cre. Upon Mx1 induction with pIpC in PPAR!fl/-#Mx1Cre mice, Cre
recombines the single PPAR! allele creating a conditional knockout (Jones et al., 2002,
Guan et al., 2005, Jones et al., 2005). These induced conditional KO mice will be referred
to as &PPAR!. Thus, &PPAR! mice allowed the targeted disruption of PPAR! in the
three most important cell types – vascular endothelium, VSMC and macrophages
(Akiyama et al., 2002, Guan et al., 2005) – involved in vascular remodeling whereas,
littermates not induced with pIpC injections served as controls. In addition, Mx1Cre
transgenic mice and pIpC-induced PPAR!fl/- mice were also used to examine AGP- and
ROSI-induced vascular wall remodeling.
2.2.6

Monitoring PPAR!! Recombination

Genotyping of Mx1/Cre#PPAR!fl/- and PPAR!fl/- mice was done as described by
Jones et al.(Jones et al., 2002). The position of the genotyping primers and their
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respective PCR products is shown in Figure 2-1A and B. Examples of the wild-type
(WT) Mx1/Cre#PPAR!fl/- genotype (mouse #23) and PPAR!fl/- genotype (mouse #24) are
shown in Figure 2-1C. The following genotyping primers were used: A1, (forward) 5’TACTTAATGTCATGATGATCTGT-3’; A2, (reverse) 5’-GATAAGACAGCACAA
CAATGTTC-3’; B1, (reverse) 5’-GCTCCTGAGTGCTAATATTAAAG-3’; and B2,
(forward) 5’-CCATGGACTAATGCTGTAATATTA-3’ Cre-specific primers – (forward)
5’-ACCTGAAGATGTTCGCGATTATCT-3’ and (reverse) 5’-ACCGTCAGTACGTGA
GATATCTT-3’ – were used, yielding a 370-bp fragment (Figure 2-1D). Amplification
was done using a 200-ng template for 40 cycles (Tag DNA Polymerase; New England
Biolabs; Ipswich, MA). Two weeks after pIpC induction of young animals RT-PCR for
PPAR! mRNA expression was done using peritoneal macrophages, carotid arteries, or
abdominal aorta samples (Figure 2-1D). For PPAR! the 5’-GGAAAGACAACAGACAA
ATCACC-3’ (forward) and 5’-ATTCAGCTTGAGCTGCAGTTC-3’ (reverse) primers
were used the amplicon yielding a 558 bp fragment. For quantitative monitoring of
pIpC-induced Mx1Cre-mediated recombination of PPAR!, 18 mice were randomly
divided into two equal groups. One group was injected i.p. with 250 µl of pIpC (2 mg/ml)
on days 1, 3, 5, and 7; the others received vehicle. Two weeks after the last injection, the
mice were anesthetized with ketamine and xylazine and injected i.p. with 5 µl of sterile
PBS. About 5 # 105-106 macrophages per mouse were collected from the peritoneal wash
by centrifugation and the common carotid artery and the aorta were dissected. RNA
purified using TRIzol was pooled from three mice, yielding three samples (treated
separately) from the nine mice. One µg of RNA was digested with DNase I and used for
the subsequent synthesis of cDNA, using the First Strand Synthesis kit. The following
primer pairs were used: PPAR!, (forward) 5’-CATGCTTGTGAAGGATGCAA-3’ and
(reverse) 5’-CCCAAACCTGATGGCATT-3’; and GAPDH, (forward) 5’-CTGCACCAC
CAACTGCTTAG-3’ and (reverse) 5’-GGGCCATCCACAGTCTTCT-3’. Amplification
was performed for 40 cycles at 94ºC/15 sec and 60ºC/60 sec. Quantitative values were
obtained from the Ct. &Ct was defined by subtracting the average Ct value of PPAR!
from the corresponding Ct value of the GAPDH gene in a given sample. Results were
expressed as fold difference (N) in gene expression relative to GAPDH, where N = 2(&Ct
pIpC - &Ct vehicle). In peritoneal macrophages, the PPAR! transcript number decreased
by 95% after pIpC induction, whereas in the carotid tissue the decrease was 87% (Figure
2-1E).
2.2.7

Mouse Model of Neointima Induction

The surgical procedure for exposing and cannulating the external carotid artery
originally developed by Yoshida et al. (Yoshida et al., 2003) rats was adopted to mice.
Briefly, the right carotid arteries of anesthetized adult (8-12 week) and sex-matched mice
(20 – 30 g) was surgically exposed. The caudal origin of the common carotid artery was
ligated using a vessel clip, followed by exposure and ligation of the internal carotid artery
above the bifurcation. The external carotid artery was then exposed and a polyethylene
catheter was inserted into the external carotid such that it never reached the common
carotid artery, thereby avoiding mechanical injury to this segment of the vessel. The clip
occluding the common carotid artery was temporarily released, and the vessel was rinsed
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with a retrograde injection of 100#l physiological saline to remove residual blood. The
vessel was again clipped, and 50 #l of treatment solution containing 5#M AGP or ROSI
dissolved in 3% DMSO PBS (vehicle) was injected under pressure. After 60 min of
incubation, the cannula was withdrawn, the external carotid artery was ligated, and blood
flow was restored by removing the clips. Three weeks post surgery the animals were
euthanized, and the common carotid artery from the jugular arch to the bifurcation was
dissected on both sides, snap frozen in liquid N2-cooled isopentane and processed for
histological analysis. Cryostat sections (~5 µm) were cut and stained with hematoxylin
and eosin, Masson's trichrome stain (Richard-Allan Scientific Inc.) or processed for
immunohistological staining. Intima-to-media ratios were measured using the NIH Image
(version 1.62) software. Groups consisted of four-to-ten animals per treatment or control
group. Intima-to-media ratios (mean ± SEM) were compared between the appropriate
groups using student’s t-test and p < 0.05 was considered statistically significant.
2.3
2.3.1

RESULT

Differential Effects of AGP and ROSI on Injury-Induced Neointima

Several literature reports describe the inhibitory effect of the PPAR! agonist
ROSI on injury-induced neointima (Lim et al., 2006, Lee et al., 2009). In contrast, in the
non-injury model using topical application of ROSI or LPA we and others (Yoshida et
al., 2003, Zhang et al., 2004) have found that these PPAR! agonists elicited arterial wall
remodeling that includes neointimal growth. To resolve this apparent contradiction, we
hypothesized that the mechanisms causing neointima differ between the injury and the
non-injury models. Consequently, these agents might exert different effects in these two
models. To examine this possibility, we applied a balloon injury model of the rat carotid
followed by ROSI or AGP treatments. The injury-induced neointima increased
significantly by AGP application following injury (p < 0.02, Figure 2-2). However, in
agreement with previous reports, ROSI application following balloon injury attenuated
neointima formation; although, this attenuation was not statistically significant (p=0.24).
These observations suggest different mechanisms for AGP and ROSI in this balloon
injury model and warn against a direct comparison between this and the non-injury
model.
2.3.2

Expression of LPA GPCR Subtypes in the Mouse Carotid

QPCR was used to assess the expression of LPA1-5 GPCR. Transcripts were
detected with a rank order of LPA1 > LPA4 >> LPA2 = LPA3 > LPA5 (Figure 2-3A) in
both the carotid and aortic tissue (not shown). LPA1, LPA2, LPA3, and LPA4 GPCR are
12-, 30-, 100-, and 1.5-times less sensitive to AGP than LPA (Fujiwara et al., 2005,
Williams et al., 2009), respectively. In contrast, AGP is more potent than LPA inducing
arterial wall remodeling (Zhang et al., 2004). LPA4 KO mice only became available after
the conclusion of the experiments presented herein and were not included in the present
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Figure 2-2
Effects of 10 !M AGP or ROSI on neointima induced by balloon
injury of the rat carotid artery.
(A) Intima-to-media ratios three weeks after balloon injury followed by a one-hour
treatment with vehicle, 10 #M AGP or ROSI. (B, C, and D) Representative cross sections
of vehicle-, AGP-, and ROSI-treated carotid arteries. The calibration bar is 200 #m.
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Figure 2-3
carotids

AGP and ROSI elicit arterial wall remodeling in C57/BL6 mouse

(A) Quantitative RT-PCR of LPA GPCR expression in the mouse carotid artery. (B)
Trichrome-stained cross section of a C57/BL6 mouse carotid treated with vehicle. (C and
D) Cross section of a trichrome-stained mouse common carotid artery three weeks after
intralumenal application of 2.5 µM AGP. (E and F) Cross section of a mouse common
carotid artery three weeks after intralumenal application of 2.5 µM ROSI. Trichrome
staining, the bars are 100 µm. Note the multi-layered neointima and changes in the media
indicated by the blue stain.
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study. Although LPA3 was reported to prefer unsaturated LPA species over saturated
ones (Bandoh et al., 2000), this is not unique to LPA3 but also found at LPA1 and LPA2
(Fujiwara et al., 2005). Due to the 100-fold lesser potency of AGP over LPA at the LPA3
GPCR combined with the low abundance of its transcripts in the carotid LPA3 KOs were
not included in the study. The ligand selectivity of the LPA GPCR tend to discount but
do not exclude the role of these receptors in AGP-induced arterial wall remodeling.
2.3.3 Lumenally Applied AGP and ROSI Elicit Vascular Remodeling in the
Uninjured Mouse Carotid Artery
In an effort to examine the contribution of the different cell surface and
intracellular LPA receptors to AGP-elicited vascular remodeling we adopted the carotid
infusion model to mice. Similarly to our findings in rats (Zhang et al., 2004), infusion of
vehicle to the mouse carotid failed to induce remodeling (Figure 2-3B, Figure 2-4A). In
contrast, a brief 60 min application of 2.5 #M AGP elicited multilayered neointima
(Figure 2-3C). The PPAR! agonist ROSI (2.5 #M) also elicited arterial wall remodeling
(Figure 2-3E). No apparent morphologically distinguishable features were found between
intimal thickening elicited by AGP or ROSI. Neointima development was accompanied
by changes in the media as indicated by the blue staining in the trichrome-stained slides
(Figure 2-3D and E) in segments of the common carotid artery not subjected to
mechanical injury either by cannulation or clipping. The arteries taken from the
contralateral side showed no visible alteration upon microscopic observation (data not
shown). The beginning of intimal thickening was clearly observed by the second week
and progressed up to the fourth week, the latest time point examined. The neointimal
layer developed in response to AGP was not stained with anti-CD31 (Figure 2-4C) but
strongly reacted with anti-"SMA antibody (Figure 2-4D). Using double staining, only a
few cells in the neointima expressed the CD68 marker (Figure 2-4E) and CD11b positive
cells were scarce (Figure 2-4D). Similar immunocytological findings were noted in the
ROSI treated mice (Figure 2-5A-F).
2.3.4

Neointimal Responses in LPA GPCR KO Mice

LPA1, LPA2, and DKO mice were subjected to intralumenal application of 2.5
#M AGP or ROSI and the carotids were isolated 3 weeks later and neointima formation
was quantified. Intima-to-media ratio measurements in LPA1, LPA2, and DKO mice
showed that AGP (Figure 2-6A, Figure 2-7A) and ROSI (Figure 2-6B) elicited neointima
development that was indistinguishable from that seen in WT mice. The cells comprising
the neointima were not stained with anti-CD31 (Figure 2-7B) but showed strong
immunoreactivity with the anti-"SMA antibody (Figure 2-7C). The neointima contained
scattered CD68 positive cells (Figure 2-7D), whereas CD11b positive cells were scarce
(Figure 2-7E). Double staining with anti-"SMA and CD68 (not shown) or CD11b
(Figure 2-7F) antibodies showed distinct populations of cells expressing the two markers
that was similar to the staining patterns seen in WT animals (Figure 2-4E and F, Figure
2-5D-F). The immunohistological staining of the single KO mice showed features (not
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Figure 2-4
Histological and immunohistological staining of neointima in C57/BL6
mouse carotids three weeks after intralumenal application of 2.5 !M AGP
(A) Vehicle injected control carotid artery shows no neointima. (B) AGP-treatment
causes concentric neointima with capillary formation within the neointima. (C)
Anti-CD31 staining shows single layer of staining and lack of staining in the neointimal
layers. (D) Anti-"SMA staining shows intensive immunoreactivity in the neointimal
layers. (E) Merged image of anti-CD68 (green) and anti-"SMA (red) staining shows
scattered cells bearing this marker in the neointima and no double stained cells in this
merged image. (F) Anti-CD11b stained cells are few and anti-"SMA double positive
cells are not visible. Calibration bar is 100 #m.
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Figure 2-5
Histological and immunohistological staining of neointima three
weeks after intralumenal application of 2.5 !M ROSI into the carotid of WT
C57BL/6 mice
(A) Masson’s trichrome stain shows multi-layered neointima. (B) Anti-CD31 staining
shows lack of staining in the neointimal layers. (C) Anti-"SMA staining shows intensive
positivity of the neointimal layers. (D) Anti-CD68 stains cells bearing this marker in the
neointima and at the media-adventitia boundary. (E) No anti-CD11b stained cells are
detected in the neointima. (F) Merged image of double staining with anti-CD11b (green)
and anti-"SMA (red) shows distinct populations of cells bearing only one but not both
markers. Calibration bar is 100 #m.
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Figure 2-6
mice

Intima-to-media ratios measured in WT and LPA1, LPA2, and DKO

Effect of 2.5 #M intralumenal application of either AGP (A) or ROSI (B) three weeks
after treatment. Note the similar intima-to-media ratios elicited by the treatments
regardless of the genotype of the mice. No statistically significant differences were found
between the different KOs.
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Figure 2-7
Immunohistological phenotyping of neointima three weeks after
intralumenal application of 5 !M AGP in DKO mice
(A) Masson trichrome-stained carotid shows multi-layered neointima. (B) Anti-CD31
staining shows lack of staining in the neointimal layers. (C) Anti-"SMA staining shows
intensive immunoreactivity in the neointimal layers. (D) Anti-CD68 staining shows
positive cells in the neointima. (E) Anti-CD11b stained cells are few and localized at the
media-to-adventitia border. (F) Merged double staining for CD11b (green) and
anti-"SMA staining shows no double positive cell. Calibration bar is 100 #m.
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shown) that were similar to those seen in DKO or WT mice. These observations did not
support the requirement for LPA1 and LPA2 GPCR in AGP- and ROSI-elicited arterial
wall remodeling; thus we focused our investigation to PPAR!.
2.3.5

Neointimal Responses in Conditional PPAR!! KO Mice

Knocking out PPAR! causes embryonic lethality, hence we were limited to the
availability of conditional KOs that reach adulthood. We chose the Mx1Cre#PPAR!fl/mouse because in this strain we could experimentally activate Cre-mediated
recombination through the Mx1 promoter in the endothelium, VSMC, and macrophages
(Akiyama et al., 2002, Schneider et al., 2003). The added benefit of inducible
Cre-mediated recombination was that we could compare induced and uninduced
littermates. In addition, we examined mice from the parental strains Mx1Cre and
PPAR!fl/- for their responses to intracarotid application of AGP and ROSI. In these
experiments Mx1Cre mice showed neointima similar to WT mice (Figure 2-8A, Figure
2-9A and B). PPAR!fl/- littermate mice were randomly assigned to two groups, one of
which received vehicle, the other was induced with pIpC three weeks prior to carotid
surgeries. The uninduced (vehicle injected) group was included to determine whether
deletion of one PPAR! allele has any effect on arterial wall remodeling elicited by the
two compounds. The pIpC induced control group was designed to assess the effect of
pIpC pretreatment on AGP- and ROSI-elicited arterial wall remodeling. Three weeks
after these pretreatments the animals were exposed to either vehicle, 2.5 #M AGP, or
ROSI for 1 h. After 21 days post carotid surgery the arteries were processed for histology
and immunohistology to examine the arterial wall. Determination of the intima-to-media
ratio regardless of pretreatment by vehicle or pIpC in the AGP-treated animals showed
increases that were identical to those seen in WT animals (Figure 2-8B and G). Similarly,
when ROSI was infused into the carotids of pretreated animals the intima-to-media ratio
increased (Figure 2-8H, Figure 2-9C and D). These results indicate that neither presence
of only a single PPAR! allele nor pretreatment with pIpC abolished arterial remodeling
elicited by AGP or ROSI.
Littermates of Mx1Cre#PPAR!fl/- animals were randomly assigned to two
pretreatment groups to receive either pIpC induction or vehicle. After a 3-week period the
carotids of these animals were exposed to either 2.5 #M AGP, 2.5 #M ROSI, or vehicle.
Carotid arteries of vehicle pretreated Mx1Cre#PPAR!fl/- animals three weeks after AGP
or ROSI treatment showed significant increases in intima-to-media ratio (Figure 2-8C, G,
and H, Figure 2-9E and F). The neointima-to-media ratios were similar to that seen in
WT animals or PPAR!fl/- animals, establishing that the Mx1Cre#PPAR!fl/- genetic
background without pIpC induced Mx1Cre recombination develops arterial wall
remodeling in response to AGP or ROSI. In sharp contrast, in the pIpC-induced &PPAR!
animals AGP or ROSI treatment failed to alter the intima-to-media ratio (Figure 2-8D
and F-H, Figure 2-9G and H). These results indicate that conditional KO of PPAR!
completely abolished the arterial wall remodeling elicited by AGP or ROSI. Carotid
arteries obtained from every group of animals were also stained with anti-CD31, anti"SMA, anti-CD68, and anti-CD11b antibodies. In those groups of animals that showed
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Figure 2-8
Effect of Mx1Cre-mediated conditional knock out of PPAR!! on
AGP-induced neointima
(A) Trichrome staining of a representative Mx1Cre transgenic mouse carotid three weeks
after exposure to 2.5 #M AGP. (B) Representative trichrome-stained carotid of a
pIpC-induced PPAR!fl/- mouse three weeks after AGP treatment. (C) Trichrome-stained
mouse carotid from a Mx1Cre#PPAR!fl/- mouse without pIpC induction three weeks after
exposure to 2.5 #M AGP. (D) Trichrome-stained carotid from a pIpC-induced &PPAR!
mouse three weeks after AGP treatment. Note the complete lack of neointima
development. (E) Anti-"SMA staining of an uninduced Mx1Cre#PPAR!fl/- mouse three
weeks after AGP treatment. Note the "SMA positive neointimal cells inside the internal
elastic lamina (IEL) that shows red autofluorescence. EEL- external elastic lamina. (F)
Anti-"SMA staining of a pIpC-induced &PPAR! mouse three weeks after AGP
treatment. Note the complete lack of "SMA staining inside the IEL. Calibartion bars are
100 #m. Intima to media ratios in mice with or without pIpC induction three weeks after
exposure to 2.5 #m AGP (G) or ROSI (H). Asterisks denote significant differences to
uninduced vehicle-treated Mx1Cre#PPAR!fl/- mice (p< 0.05, n= 5-10 mouse per group).
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Figure 2-9
Effect of Mx1Cre-mediated conditional knock out of PPAR!! on
ROSI-induced neointima
Trichrome (A) and anti-"SMA (B) staining of a pIpC-treated Mx1Cre mouse carotid
three weeks after treatment with 2.5 #M ROSI. Trichorme (C) and anti-"SMA (D)
staining of a carotid from a pIpC-induced PPAR!fl/- mouse. Trichorme (E) and
anti-"SMA (F) staining of a carotid from a non-pIpC-induced Mx1Cre#PPAR!fl/- mouse
carotid. Note the anti-"SMA positive neointimal cells inside the IEL. Trichorme (G) and
anti-"SMA (H) staining of an pIpC-induced &PPAR! mouse three weeks after ROSI
treatment. Note the complete lack of "SMA staining inside the IEL. Calibartion bars are
100 #m.
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increased intima-to-media ratios the immunohistological profile was qualitatively
indistinguishable form that of the WT treated with AGP or ROSI. In &PPAR! animals
that showed no alterations in the intima-to-media ratio we did not observed an increase in
SMA positive cells (Figure 2-8F, Figure 2-9H) or alterations in the CD68 or CD11b (not
shown) marker-bearing cell populations.
2.4

DISCUSSION

Arterial wall remodeling is considered a prelude to atherosclerotic disease and its
pharmacological modulation is of significance in the prevention of several associated
pathologies. Injury-induced and post-angioplasty arterial wall remodeling also represent
human pathologies that would benefit from pharmacological intervention. The growth
factor-like phospholipid mediator LPA has been shown to induce arterial wall remodeling
in the absence of injury following only a brief 1-h-long topical application into the lumen
of the carotid artery (Yoshida et al., 2003, Zhang et al., 2004). In the present study we
sought genetic evidence for the role of LPA1 and LPA2 GPCRs and the intracellular LPA
receptor PPAR! in this chemically-induced model of arterial wall remodeling.
First, we attempted to resolve the apparent contradiction between chronic
ROSI-induced attenuation of injury-elicited neointima (Lim et al., 2006, Lee et al., 2009)
and the ROSI-induced neointimal response in the non-injury model by comparing AGP
and ROSI effects in the two models. We hypothesized that the mechanisms underlying
neointima formation in the chemically-induced and injury-induced models differ leading
to the opposite outcome in the response to ROSI application. In the balloon injury model
AGP significantly augmented the intima-to-media ratio over that elicited by the injury
(Figure 2-2A-C). In contrast, ROSI treatment did not cause either a significant
attenuation or augmentation in the intima-to-media ratio relative to the injury control,
although the neointima in this treatment group was lesser than in the injury control group
(Figure 2-2A and D). This set of experiments clearly indicates that ROSI and AGP
application to an injured vessel with disrupted epithelium elicit different outcomes.
Future experiments will be conducted using the KO mouse models to evaluate the role of
LPA GPCR and PPAR! after vessel wall injury.
Our second objective was to establish and validate a chemically-induced arterial
remodeling model in the mouse. We scaled down the treatment from the previously
reported rat model (Yoshida et al., 2003, Zhang et al., 2004) and found that in C57BL/6
mice, which represent the genetic background of our knockouts, lumenal application of
AGP elicited carotid remodeling at low micromolar concentrations (Figure 2-3C and D).
No such changes were found in vehicle treated (Figure 2-3B) or sham operated animals
or in the contralateral carotid of AGP-treated mice. Just as in the rat, in mice luminal
intracarotid application of ROSI (Figure 2-3E and F) mimicked the effects of AGP when
applied at the same concentration and over the same time course. This observation
extended the utility of this model from the rat to the mouse, creating the opportunity for
inclusion of transgenic and knockout mice in our experiments.
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The cellular markers of the treated carotids were examined using antibodies
specific to Von Willebrand factor (CD31), "SMA, the pan macrophage marker CD68,
and the CD11b marker, which is expressed by tissue macrophages including dendritic
cells. Carotid arteries collected from AGP- or ROSI-treated WT mice showed a single
layer of CD31 positive cell layer (Figure 2-4C, Figure 2-5B) indicating that the cells in
the neointima lack this endothelial cell marker. The neointimal layer showed very strong
staining with the "SMA marker (Figure 2-4D, Figure 2-5C) suggesting that the AGP- or
ROSI-induced neointima involves the expansion of a cell lineage expressing this smooth
muscle cells and myofibroblast marker. Infiltration by cells of the macrophage lineage
has been noted in atherosclerotic lesions as well as in the injury-induced neointima (Levy
et al., 2007, Papaspyridonos et al., 2008, Seimon et al., 2009). We applied double
immunostaining for "SMA cells and CD68 markers in search for double positive cells
but failed to detect double positive cells (Figure 2-4E). Immunostaining for the CD11b
marker showed few cells localized to the media-adventitia boundary. We did not detect
double CD11b and "SMA immunoreactive cells (Figure 2-4F, Figure 2-5F). These
observations provide important insight into the mechanism of AGP-induced arterial wall
remodeling. It has been reported that LPA blocks the egress of macrophage/dendritic
cells from the subendothelium leading to their accumulation (Llodra et al., 2004) and our
experiments showed few CD68 and CD11b positive monocytoid cells within multiple
layers of "SMA positive cells. Thus in this model the overwhelming majority of
neointimal cells expresses "SMA marker which tends to favor a hypothesis that the
vascular smooth muscle lineage dominates the cell type responsive to AGP or ROSI
stimulation. Whether macrophages are retained initially and cytokines derived from them
lead to a secondary immigration and/or proliferation of "SMA positive cells remains to
be subject in future studies. Even if this hypothesis will turn out to be correct, the
initiating signal that attracts macrophages into the subendothelium would have to
originate from the AGP-activation of cells resident to the normal carotid wall. LPA
through the LPA1 and LPA2 GPCRs has been shown to induce the expression of
proinflammatory chemokines including MIP-1beta, IL-8, and MCP-1(Lin and Boyce,
2005, Lin et al., 2006, Kaneyuki et al., 2007). Thus if LPA1 and/or LPA2 receptors were
required for the accumulation of macrophages leading to neointima, we should have
found no macrophage accumulation and neointima in the DKO mice but this was not
supported by the experimental findings. Because in rats we found that the effects of LPA
or AGP on carotid artery remodeling were indistinguishable from that of ROSI, we tested
this compound also. The cellular composition of the ROSI-elicited neointima resembled
those in AGP treated carotids (Figure 2-5). These similarities provide added
circumstantial support to the hypothesis that these compounds activate a similar
mechanism leading to arterial wall remodeling.
LPA1, LPA2, and DKO mice have been generated and show no spontaneous
vascular pathology (Contos et al., 2002). Because LPA1 and LPA2 both are activated by
AGP (Fujiwara et al., 2005), we focused initially on their role in LPA-induced arterial
wall remodeling. Because of the availability of these single KOs, we also crossed them
and established DKO animals. Both AGP and ROSI elicited neointima in the three KO
strains that were statistically and immunohistologically indistinguishable from that seen
in the WT mice (Figure 2-6, Figure 2-7). LPA GPCR are activated by both saturated and
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unsaturated acyl-LPA with a rank order of potency of acyl-LPA > alkyl-GP (Fujiwara et
al., 2005, Williams et al., 2009). Only LPA5 prefers AGP over LPA (Panchatcharam et
al., 2008, Williams et al., 2009) but transcripts of this receptor subtype were the least
abundant in the mouse carotid (Figure 2-3A). Moreover, LPA GPCRs do not show
stereoselectivity to AGP (Yokoyama et al., 2002). The structure-activity relationship for
LPA-induced neointima formation is markedly different from that described for LPA
GPCR (Zhang et al., 2004): it shows a rank order of alkyl-GP > acyl-LPA, only
unsaturated but not saturated fatty acyl species stimulate lesion formation, and the effect
shows stereoselectivity for 1-O-AGP over 3-O-AGP. Whereas, LPA-induced cell VSMC
proliferation and migration is blocked by pertussis toxin (Tokumura et al., 1994),
pretreatment by this toxin only slightly attenuated, but did not abolish neointima
formation (Zhang et al., 2004). Diacylglycerol pyrophosphate, a competitive antagonist
of the LPA3 and LPA1 receptors (Fischer et al., 2001), produced only a partial inhibition
of neointima formation. Based on the present results from the LPA GPCR KOs we now
expand our previous indirect pharmacological observations and conclude that neither
LPA1 nor LPA2 receptors are required for AGP- and ROSI-induced arterial wall
remodeling.
Because the specific PPAR! antagonist GW9662 fully abolished arterial wall
remodeling in rat carotids exposed to AGP, or ROSI, we examined the effect of these
agents in conditional PPAR! KO mice. Knocking out PPAR! leads to embryonic lethality
and the inducible conditional KO of PPAR! activated by the IFN-regulated Mx1Cre
transgene offers an ideal model system in our case because the Mx1Cre is predominantly
expressed in endothelial cells, vascular smooth muscle cells and in also in macrophages
(Akiyama et al., 2002, Schneider et al., 2003), which represent the three cell types
implicated in the literature in neointima formation. The inducible Mx1Cre-regulated
recombination of the single floxed PPAR! allele also provided littermate controls that
were not exposed to pIpC induction. We also evaluated the effect of pIpC induction in
PPAR!fl/- animals three weeks prior to AGP or ROSI treatment of the carotid artery to
determine whether it would alter the responsiveness of the arterial wall. Quantitative
RT-PCR for PPAR! showed that three weeks was sufficient to induce the recombination
of the floxed PPAR! allele with high penetration although recombination was not
complete (Figure 2-1). Topical intracarotid application of AGP or ROSI in pIpC-induced
PPAR!fl/- animals elicited arterial wall remodeling with intima-to-media ratio
indistinguishable from that seen in WT animals (Figure 2-8G and H). These findings
indicate that pIpC induction does not affect the arterial wall remodeling elicited by AGP
and ROSI. Furthermore, these results also establish that deletion of one PPAR! allele
does not attenuate AGP- or ROSI-induced neontima. Uninduced Mx1Cre#PPAR!fl/developed neointima in response to the treatments indicating that spontaneous
recombination and the ensuing deletion of this nuclear hormone receptor, if present, is
not sufficient to abolish arterial wall remodeling. The immunohistological observations
of the arterial wall of these AGP or ROSI treated mice showed qualitative features that
resembled those seen in WT animals (Figure 2-8, Figure 2-9). In sharp contrast, in
&PPAR! mice AGP or ROSI failed to cause a significant change in intima-to-media ratio
(Figure 2-8G and H).
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Immunohistological examination of carotid arteries taken from these mice showed
no "SMA positive cells between the endothelium and the internal elastic lamina (Figure
2-8F, Figure 2-9H). These observations taken together provide genetic evidence for the
requirement of PPAR! in the arterial remodeling elicited by AGP and ROSI. The present
findings combined with our previous report showing that the PPAR! antagonist GW9662
fully blocked AGP- and ROSI-induced arterial wall remodeling in rats, now provide two
independent lines of evidence for the requirement of PPAR! in neointima development in
the non-injury model.
LPA and AGP activate platelets, stimulate the formation of platelet-monocyte
aggregates (Fueller et al., 2003), and accumulate in the lipid rich core of human
atherosclerotic plaques. LPA production in blood is linked to platelet activation (Sano et
al., 2002). LPA activates the expression of V-CAM and E-selectin adhesion molecules in
endothelial cells which promote cell adherence and invasion of the vessel wall by blood
cells (Rizza et al., 1999). LPA also stimulates proinflammatory cytokine production
(Kaneyuki et al., 2007, Lin et al., 2007) and inhibits the egress of macrophages from the
subendothelium (Llodra et al., 2004). This abundance of evidence combined with our
present observations support the role of LPA in vascular wall remodeling and the present
study underlines the importance of PPAR! as an important molecular target in this
pathology.
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CHAPTER 3. PHOSPHOLIPASE D2-DEPENDENT INHIBITION OF THE
NUCLEAR HORMONE RECEPTOR PPAR!! BY CYCLIC PHOSPHATIDIC
ACID*
3.1

INTRODUCTION

PPAR! plays an essential role in regulating lipid and glucose homeostasis, cell
proliferation, apoptosis, and inflammation (Ricote and Glass, 2007, Tontonoz and
Spiegelman, 2008). These pathways have a direct impact on human diseases, in particular
in diabetes(Lehmann et al., 1995), atherosclerosis(Li et al., 2000), and cancer (Sarraf et
al., 1998). Synthetic agonists of PPAR! include the thiazolidinedione (TZD) class of
drugs, which are widely used to improve insulin sensitivity in type 2 diabetes.
Physiological agonists of PPAR! include 15d-PGJ2 (Forman et al., 1995), modified fatty
acids (Nagy et al., 1998, Li et al., 2008), select species of lysophosphatidic acid
(1-acyl-2-hydroxy-sn-glycero-3-phosphate, LPA; Figure 3-1A) (McIntyre et al., 2003),
and oxidized phospholipids (Tontonoz et al., 1998). Another phospholipid,
1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine has recently been recognized as a
physiologically relevant agonist of PPAR" (Chakravarthy et al., 2009). Despite the
beneficial effects of PPAR! on glucose and lipid homeostasis, excess PPAR! activity can
be deleterious. PPAR! agonists promote adipocytic differentiation of 3T3-L1 cells and
also stimulate the uptake of low-density lipoprotein (LDL) by macrophages, leading to
foam cell formation in the arterial wall (Tontonoz et al., 1998, Moore et al., 2001). When
applied topically to the carotid arterial wall in rodents, select molecular species of LPA
and the TZD drug rosiglitazone (ROSI) induce PPAR!-mediated intimal thickening
(Zhang et al., 2004, Cheng et al., 2009). Alkyl-ether analogs of LPA accumulate in the
atherogenic oxidized-LDL (Zhang et al., 2004) and human atherosclerotic plaques
(Rother et al., 2003), and are potent agonists of PPAR! (Tsukahara et al., 2006). This led
us to hypothesize that select LPA analogs could be endogenous regulators of PPAR!;
hence, we investigated the structure-activity relationship of activation by naturally
occurring lysophospholipids (Figure 3-1A).
* Adapted with permission. Tsukahara T, Tsukahara R, Fujiwara Y, Yue J, Cheng Y,
Guo H, Bolen A, Zhang C, Balazs L, Re F, Du G, Frohman MA, Baker DL, Parrill AL,
Uchiyama A, Kobayashi T, Murakami-Murofushi K, Tigyi G (2010) Phospholipase D2
dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic
phosphatidic acid. Mol Cell 39:421-432.
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Figure 3-1

CPA is an antagonist of PPAR"

(A) Structures of the lysophospholipids and ROSI. (B) CPA does not activate
PPAR"-dependent PPRE-ACox-Luc expression. CV-1 cells were transfected with
ACox-luc plus pcDNA3.1-PPAR" and treated for 20 h with 5 mM each of ROSI, LPA
18:1, AGP 18:1, CPA 18:1, MG, AG, or OA. Luciferase activities are presented as
relative light units (RLU, mean ± SEM, n = 4, *p < 0.05, **p < 0.01). (C) Different
molecular species of CPA and CGP dose-dependently suppress ROSI-induced
PPAR"-dependent PPRE-TK-Luc reporter gene activation in B103 cells. B103 cells
(3.0$104) were transfected with pMH100-PPRE-TK-Luc, pCMX-PPAR"-Gal4, and
pSV-$-gal. After transfection, the cells were exposed to CPA or CGP (0.1, 1 and 10 #M)
with or without ROSI (10 #M) for 20h, and reporter gene expression measured (mean ±
SEM, n=4). (D and E) Competitive displacement of 5 nM [3H]-ROSI or [32P]-AGP from
PPAR"-LBD was determined using 2.5 mM cold ROSI, AGP, or CPA. (F) CPA 18:1 and
CGP 18:1 displace [3H]-ROSI from purified LBD of PPAR". Competition binding was
performed using 5 nM [3H]-ROSI and increasing concentrations of CPA or CGP. (G)
BODIPY-CPA competitively displaces [3H]-ROSI from PPAR" LBD. Competition
biding assay was performed using purified 3 µg PPAR"-LBD with 5 nM [3H]-ROSI and
increasing concentrations of either ROSI or BODIPY-CPA competitor. (H and I) Uptake
of BODIPY-CPA (3 nmoles) into RAW264.7 macrophages. The rate of accumulation
and the metabolic fate of labeled CPA were monitored in the medium (M or circles) and
macrophages (C or squares) using TLC. The major fluorescent metabolite observed
co-migrated with a standard for BODIPY-FA (fatty acid), indicating phospholipase/acyl
transferase action. BODIPY-LPA was not detected. (J) BODIPY-CPA rapidly
accumulated in the cell-associated pool and was present in the cytoplasm. Representative
fluorescent microscopy image of 3 nmole BODIPY-CPA-treated RAW264.7
macrophages after 0.5 min and 30 min exposure (bar, 50 mm).
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3.2
3.2.1

EXPERIMENTAL PROCEDURES

Cells

All cell lines were from ATCC unless stated otherwise. MDA-MB-231 cells were
grown in Leibovitz’s L-15 medium (Gibco) containing 10% (v/v) FBS, 100 U/ml
penicillin, and 10 µg/ml streptomycin. CV-1, B103 (rat neuroblastoma cells, from Dr.
Jerold Chun, Scripps Institute, La Jolla, CA), RAW 264.7 mouse macrophage cells and
3T3-L1 mouse fibroblast cells were grown in Dulbecco’s modified Eagle’s medium
containing 10% FBS, penicillin, streptomycin, and 1 mM sodium pyruvate. Tetracycline
operator-regulated PLD1 and PLD2 transfected CHO have been characterized elsewhere
(Du et al., 2004) and were grown in Ham’s F12 medium with 5% FBS. Induction of PLD
expression was done by 1.5 µg/ml doxycycline (Sigma) for 24 h. Sf-9 insect cells
(Invitrogen) were grown in serum-free medium Sf-900 II (Life Sciences).
3.2.2

Ligand-Binding Assays

Ligand binding assays were preformed as described in detail previously
(Tsukahara et al., 2006).
3.2.3

PPAR Reporter Gene Assays

Determination of PPAR!, !/", and " activation was done in CV-1 cells
(endogenously express LPA1/2/3) or B103 cells (lack endogenous LPA1/2/3 receptors and
PPAR") transfected with 125 ng of the appropriate reporter gene
(pGL3-PPRE-acyl-CoA oxidase luciferase or in some experiments with
MH100-PPRE-TK-luciferase) and 62.5 ng of pcDNA3.1-PPAR" or pCMX-PPAR"-Gal4
and 12.5 ng of pSV–!-galactosidase (Promega) construct as previously reported
(Tsukahara et al., 2006). To monitor activation of PPAR#, 62.5 ng of
pG4M-PPAR#-ligand binding domain and 12.5 ng of pSV-!-galactosidase or 125 ng of
17 m5$-!GLOB-luc plasmids were transfected into B103 cells using Lipofectamine
2000. For PPAR !/", we used 62.5 ng of pG4M-PPAR!/"-LBD plasmid DNA and 12.5
ng of pSV-!-galactosidase or 125 ng of 17m5$-!GLOB-luc plasmids. Twenty-four hours
after transfection, cells were treated with Opti-MEM containing 10 µM test compound
dissolved in DMSO and cultured for an additional 20 h. Luciferase activity was measured
with the Steady-Glo Luciferase Assay System (Promega) using a Fusion Alpha plate
reader (Perkin-Elmer).
3.2.4

Co-Repressor Two-Hybrid Assays

The effect of CPA on SMRT co-repressor binding to PPAR" was done as
described by Yu et al. (Yu et al., 2005). Briefly, CV-1 cells were plated onto 96-well
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plate at the density of 1.0$104 cells per well in DMEM containing 10% FBS. The next
day, the cells were transiently transfected with 71 ng of UAS-Luc, 14.3 ng of
Gal4-SMRT, 14.3 ng of pVP16-PPAR"2, and 10 ng of pSV–!-galactosidase (Promega)
using Lipofectamine LTX (Invitrogen). Twenty hours after transfection, the cells were
pretreated with various concentrations of CPA or CGP 18:1 in Opti-MEM (Invitrogen)
for 30 min, followed by treated with Opti-MEM containing 1nM ROSI for 6 h.
Luciferase and #-galactosidase activities were measured as above. Samples were run in
quintuples, and the mean ± SEM were calculated. Data are representative of at least three
independent transfections. Student’s t test was used to test for statistical analysis and
p<0.05 was considered significant.
3.2.5

Biosynthetic Labeling of Cells and Measurement of CPA Synthesis

MDA-MB-231 cells (3.5$106) or CV-1 cells (1.0$106) were serum-starved for 12
h and washed with phosphate-free medium and incubated in balanced salt solution (135
mM NaCl, 4.5 mM KCl, 1.5 mM CaCl2, 0.5 mM MgCl2, 5.6 mM glucose, 10 mM
HEPES-NaOH, pH7.2) containing 1 mCi/ml [32P]-orthophosphoric acid. After 3 h, the
labeling medium was removed, and the cells were washed 3$with Ca2+/Mg2+ free
phosphate-buffered saline (PBS) and preincubated at 37 oC in serum-free medium for 15
min. After treatment with 100 nM PMA (Fluka) for 30 min, the cells were washed once
with ice-cold PBS and collected by centrifugation. The phospholipids were extracted
(Bligh and Dyer, 1959), spotted on indicator-free high-performance silica gel TLC plates
(Whatman) and separated by two-dimensional TLC using
chloroform-methanol-acetic acid-1% sodium disulfite (100:40:12:5) solvent in the first
dimension and chloroform-methanol-ammonium hydroxide (3:6:1) in the second
dimension. Unlabeled LPA and CPA standards were mixed into the samples and
visualized by 0.01% primulin (Sigma) staining, whereas radioactivity was detected by a
Cyclone phosphorimager (Perkin-Elmer).
3.2.6

Statistical Methods

Significant differences were based on student’s t-test relative to the appropriate
control. Equilibrium binding constants (KD) were calculated from the binding data using
the Kaleida-Graph Software version 4.0 (Synergy Software).
3.3
3.3.1

RESULT

CPA Is a Specific and a High-Affinity Antagonist of PPAR$$

When testing lysophospholipids using a PPAR$ reporter gene assay, we observed
that CPA at concentrations as high as 5 %M failed to activate transcription (Figure 3-1B).
In contrast, lower concentrations of LPA 18:1 and its ether analog alkyl glycerophosphate
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(AGP 18:1) strongly activated PPAR$. Smaller chemical components of CPA namely
oleoyl glycerol (OG), alkyl glycerol (AG), and oleic acid (OA) showed weak activation.
To establish a direct interaction between CPA and the PPAR$ ligand-binding domain
(LBD), recombinant LBD was purified to examine the displacement of agonists
[3H]-ROSI (Figure 3-1C) and [32P]-AGP (Figure 3-1D) by CPA. CPA and its ether
analog 1-O-octadecyl-2,3-cyclic-glycerophosphate (CGP 18:1, Figure 3-1A) displaced
both labeled agonists, and Scatchard analysis revealed single high-affinity binding
constants at 124 ± 19 nM and 172 ± 27 nM, respectively (Figure 3-1E), which was
comparable to that of ROSI (84 ± 6 nM).
To monitor the metabolic fate and distribution of exogenously applied CPA, we
synthesized a fluorescent analog BODIPY-CPA (Figure 3-1A), which also displaced
[3H]-ROSI from the PPAR$-LBD (Figure 3-1F). BODIPY-CPA was applied to RAW
267.4 macrophages and uptake of the fluorescent lipid was determined as a function of
time (Figure 3-1G and H). BODIPY-CPA uptake peaked at 15 min before beginning to
undergo metabolism by deacylation into BODIPY-fatty acid, whereas no BODIPY-LPA
or any other metabolic product was detectable, indicating the stability of the
cyclic-phosphate ring. The cellular half-life of BODIPY-CPA in this experiment was
approximately 60 min and the label was present in both the cytoplasm and nuclei of the
cells after 30 min (Figure 3-1I). Exogenously applied CPA species inhibited
PPAR$-dependent gene expression elicited by TZDs ROSI (Figure 3-1J), pioglitazone
and troglitazone (Figure A-1A and B) in a cell-based PPAR$ reporter gene assay. The
highly homologous PPAR! and PPAR#/" receptors were neither inhibited nor activated
by CPA (Figure A-1C-F).
3.3.2 Differential Interactions between Agonists and the Antagonist CPA with the
PPAR$$ -LBD
The crystal structures of the PPAR$-LBD and the ROSI-bound complex have
previously been solved (Nolte et al., 1998). Currently no reported studies on
antagonist-bound structures of the PPAR$-LBD are currently available in the public
domain. Using a crystal structure of the highly homologous PPAR! bound to antagonist
GW6471, we generated a homology model of the inactive PPAR$-LBD complex. The
active-LBD and inactive-LBD served as targets in computational docking studies with
ROSI, AGP 18:1, and CPA 18:1 (Figure 3-2A and B). CPA 18:1 forms ion-pairing
interactions with residue R288 was previously shown for the interaction of AGP 18:1
with PPAR$-LBD (Tsukahara et al., 2006). This interaction is required for binding of the
phosphate-containing agonists. However, only the alkyl chain of AGP 18:1 showed
favorable interactions with a hydrophobic residue of the AF-12 helix, L469, in the
active-LBD (Figure 3-2B). In contrast, CPA 18:1 bound with higher affinity to the
inactive-LBD, failing to stabilize the active conformation of the AF-12 helix (Figure
3-2A). The docked positions of ROSI and AGP overlap and differ from the docked
position of CPA. This is consistent with the agonist activity of ROSI and AGP, and
corresponding lack of such activity for CPA. Although CPA does not overlap with the
docked position of AGP and ROSI, interactions with common residues occur from a
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Figure 3-2

CPA inhibits PPAR! activation and is generated by PLD

(A) Comparison of ROSI crystallized in PPAR" (1FM6) and CPA 18:1 docked into the
inactive homology model of PPAR". Blue ribbons show the backbone structure of the
inactive PPAR" homology model. The inactive homology model differs from the active
crystallographic structures only in the position of the AF-12 segment, which is shown as
a green and a red ribbon in the inactive homology model and the crystallographic
structure, respectively. Ligands are shown as ball and stick models. (B) Comparison of
AGP 18:1 docked into the activated crystallographic structure of PPAR" (1FM9) and
overlay of CPA 18:1 docked into the inactive homology model of PPAR". Note that
agonists ROSI and AGP occupy the same location and interact with residue R288, while
CPA prevents the AF-12 domain from acquiring its activated conformation (red) by
stabilizing the inactivated conformation (green). (C and D) Arginine 288 is required for
inhibition of PPAR" by CPA. Purified WT and R288A mutant PPAR" (1 %g) were
incubated with 5 nM [3H]-ROSI or [32P]-AGP 18:1 under equilibrium binding conditions
with 2.5 %M cold ROSI, AGP, and CPA, and the bound ligand quantified using a
filtration assay (mean ± SEM, n = 4). (E) ROSI-induced SMRT release from PPAR" is
dose-dependently inhibited by both CPA 18:1 and CGP 18:1. CV-1 cells were transfected
with UAS-Luc, pECE-Gal4-SMRT (containing full length SMRT), pVP16-PPAR"2, and
pSV-!-gal. After transfection, the cells were treated with CPA 18:1 or CGP 18:1 for 30
min, followed by 1nM ROSI for 6 h. Luciferase activities are presented as fold increase
(mean ± SEM, n=4, representative of 3 transfections). (F) Stimulation of biosynthetically
[32P]-orthophosphate-labeled MDA-MB-231 cells with PMA (100 nM, 30 min) leads to
CPA generation. PMA stimulation (100 nM) was also performed in the presence of either
1.5% 1-BuOH or t-BuOH. Phospholipids were separated using 2D-TLC and visualized
using phosphorimaging. Arrows point to the position of the authentic CPA standard and
asterisks indicate the position of the LPA standard. (G) CPA production in
PMA-stimulated cells is inhibited by 1-BuOH but not by t-BuOH.
Phosphorimaging-based quantification of labeled CPA after stimulation of
MDA-MB-231 cells by 100 nM PMA in the presence or not of 1.5% v/v 1-BuOH and
t-BuOH (mean cpm ± SEM, n = 4).
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different pocket. These common interactions preclude binding of CPA at the same time
as either ROSI or AGP, which explains the competitive antagonistic effect of CPA.
The phosphate group common to LPA and AGP has been previously validated to
form a salt bridge with R288 in the LBD (Tsukahara et al., 2006). The R288A mutant
loses AGP binding and activation; nevertheless, binding to and activation by ROSI
remains unchanged (Tsukahara et al., 2006). To evaluate the computationally predicted
role of R288 in CPA binding, we expressed its alanine mutant LBD recombinant protein,
and examined it for binding to [3H]-ROSI and to [32P]-AGP 18:1 (Figure 3-2C and D).
The R288A mutant bound [3H]-ROSI but did not bind [32P]-AGP 18:1. Although an
excess of unlabeled ROSI, AGP 18:1, or CPA 18:1 competed with [3H]-ROSI binding at
the WT PPAR$ LBD, only ROSI displaced the labeled ligand in the R288A mutant.
These results confirm the critical role of the predicted salt bridge between residue R288
and CPA 18:1 and support the hypothesis that CPA functions as a high-affinity antagonist
of PPAR$.
The inactive conformation of PPAR$ promotes binding of corepressor proteins.
Antagonists should prevent the agonist-induced dissociation of this complex. Using a
two-hybrid assay (Yu et al., 2005) in CV-1 cells that allows detection of the complex
formed between PPAR$ and its corepressor SMRT, we tested the effect of CPA on
ROSI-induced dissociation of this molecular complex. CPA and CGP dose-dependently
stabilized the SMRT-PPAR$ and antagonized ROSI-induced dissociation of the complex
(Figure 3-2E).
3.3.3

Activation of PLD2 Generates CPA

CPA has been detected in mammalian tissues (Murakami-Murofushi et al., 2000).
To establish a physiological role for CPA in the regulation of PPAR$, we determined
whether cellular activation of phospholipase D (PLD) can generate it because prior work
showed that the catalytic mechanism of PLD from Streptomyces chromofuscus includes
CPA as a reaction intermediate (Friedman et al., 1996). MDA-MB-231 breast cancer
cells, which express both PLD PLD1 and PLD2 isoenzymes (Eisen and Brown, 2002),
were biosynthetically labeled with [32P]-orthophosphate and stimulated with 100 nM
phorbol myristate acetate (PMA), a strong nonselective activator of both PLD isoforms.
After 30 min of stimulation the phospholipids were extracted, separated and compared to
phospholipids from vehicle-stimulated cells using two-dimensional thin layer
chromatography (2DTLC). No label was detected at the position of an authentic CPA
standard spiked into the sample in the vehicle-treated cells (Figure 3-2F). In contrast, a
spot co-migrating with the CPA standard became detectable in PMA-stimulated cells.
The hydrolysis of lysophosphatidyl choline (LPC) by PLD includes a
transphosphatidylation step that can be inhibited by the primary alcohol 1-butanol
(1-BuOH), but not by secondary alcohol 2-methyl-2-propanol (t-BuOH). When the
PMA-stimulated cells were treated with 1-BuOH, the intensity of the [32P]-CPA spot on
2DTLC was significantly reduced, whereas t-BuOH had no effect (Figure 3-2F and G).
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To determine which of the two PLD isozymes was responsible for CPA
production, we used CHO cell lines stably expressing tetracycline-inducible alleles of
wild-type (WT) or catalytically-inactive (CI) forms of PLD1 or PLD2 (Du et al., 2004).
PMA stimulation of cells with doxycycline (DOX)-induced expression of PLD1 caused a
two-fold increase in CPA production, which was similar to that observed for WT cells. In
contrast, PMA-stimulation of cells with DOX-induced PLD2 expression caused a
ten-fold increase in CPA production compared to unstimulated WT cells (Figure 3-3A)
and elevated the basal levels of CPA. However, expression of the catalytically-inactive
PLD2 (CI-PLD2) failed to amplify the PMA-induced CPA production. In the absence of
DOX induction, all four cell lines contained very low amounts of CPA, and PMA
stimulation yielded similar increases in CPA (Figure A-2A). These findings suggest that
PLD2 activation underlies the stimulus-coupled CPA production.
To obtain direct proof that PLD2 generates CPA, recombinant WT and CI-PLD2
were purified and reacted with [14C]-LPC in vitro, and the reaction products were
separated by TLC (Figure 3-3B). WT-PLD2, but not the CI-PLD2, generated [14C]-CPA
(Vmax = 190 pmol/min/mg; Km = 8 µM; Figure A-2B). Addition of 1-BuOH to this
reaction generated lysophosphatidylbutanol, whereas inclusion of t-BuOH yielded no
such product (Figure 3-3C and D). These data indicate that mammalian PLD2 is capable
of producing CPA from LPC in vitro and in vivo.
3.3.4

Physiological Stimulation of PLD2 Generates CPA

CPA levels were then quantified in unstimulated control and PMA-stimulated
MDA-MB-231 cells by liquid chromatography mass spectrometry (LC-MS). CPA was
below the detection limit in control cell extracts (Figure A-2C). Treatment with 100nM
PMA for 30 min resulted in the generation of CPA 16:0 and 18:1 (595 ± 1.5 pmol and
293 ± 25.6 pmol / 3$107 cells, respectively; Figure A-2D). Insulin is a physiological
activator of PLD2 (Slaaby et al., 2000). LC-MS quantification of CPA in
insulin-stimulated cells showed peak production with 967 ± 111.2 pmol CPA 16:0 and
573 ± 33.5 pmol CPA 18:1 per 3$107 cells, respectively (Figure A-2E). Insulin generated
higher levels of CPA compared to PMA (Figure 3-3E) that peaked at 30 min (Figure
3-3F). Insulin stimulation of CV-1 cells did not increase the biosynthetically labeled pool
of LPA (Figure 3-4A, Figure A-3A-C), indicating that the major lysophospholipid
product of PLD2 is CPA.
We extended our studies to human peripheral blood monocytes and found that
insulin, lipopolysaccharide, H2O2, or PMA stimulation of PLD2 of within 30 minutes
caused production of CPA 18:1 and 16:0 (Figure 3-4B, Figure A-2F-I). In resting
monocytes the level of CPA 16:0 and 18:0 was 0.14 and 1.5 pmole/107 cells,
respectively. After stimulation with 100 nM PMA CPA 16:0 rose ~ 1,300-fold and CPA
18:1 rose ~ 390-fold (Figure 3-4B). After stimulation with 100 nM insulin CPA 16:0 rose
8.5-fold and CPA 18:1 rose 67-fold. Addition of the PLD2 inhibitor
5-fluoro-2-indolyl des-chlorohalopemide (FIPI 750nM) inhibited production of both CPA
species (Figure 3-4B, Figure A-2G and H). Thus, physiological stimuli of PLD2 in
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Figure 3-3

In vitro and in vivo generation of CPA by PLD2

(A) PLD2 is the major source of CPA in vivo. CHO cells expressing tet-regulated WT or
CI-PLD1 or PLD2 constructs were induced by DOX and subsequently stimulated with
100 nM PMA for 30 min. Cellular phospholipids were biosynthetically labeled with 0.1
mCi [32P]-Pi for 12 h, and CPA generation quantified using phosphorimaging after
2D-TLC separation (mean ± SEM, n = 3). (B) PLD2 generates CPA in vitro.
Affinity-purified WT or CI-PLD2 (10 mg/reaction) was incubated with [14C]-LPC 16:0 at
40 ºC for 1 h. The reaction mixtures were spotted on a TLC plate and separated.
Authentic cold CPA and LPA standards were used to determine the product Rfs. (C)
1-BuOH but not t-BuOH diverts recombinant PLD2 formation of CPA to
lysophosphatidyl butanol (lyso-PtBuOH). TLC analysis of [14C]-phospholipids generated
by purified PLD2 from Sf-9 insect cells after treatment with 0.5% 1-BuOH or t-BuOH.
(D) Quantification of CPA and [14C]-lyso-PtBuOH formation by PLD2 in the presence of
0.5% 1-BuOH and t-BuOH (n = 3). N.D., not detectable. (E) LC-MS quantification of
CPA 16:0 and 18:0 after stimulation of MDA-MB-231 cells by 100 nM insulin or PMA
for 30 min (pmol mean ± SEM, n = 3). (F) Time course of insulin-stimulated CPA
production in MDA-MB-231 cells. Cells (3$106) biosynthetically labeled with
[32P]-orthophosphate were exposed to 100 nM insulin for different times and the CPA
purified using 2DTLC and quantified using liquid scintillation counting (n=3).
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Figure 3-4

PLD2 activation inhibits PPAR!

(A) Insulin stimulation elevates CPA but not LPA levels. CV-1 cells (3$106) were labeled
with [32P]-orthophosphate for 6 h and stimulated with 100 nM insulin or the DMSO
solvent for 30 min at 37 oC. Lipids were extracted, separated by 2DTLC and quantified
by phosphorimaging (n = 3). (B) CPA is generated in human peripheral blood
mononuclear cells in response to PLD2 stimulation. The cells were pretreated with the
PLD2 inhibitor FIPI (750 nM) or solvent control for 30 min prior to stimulation by 100
nM insulin, PMA 100 nM, 1 %g/ml LPS, or 1 mM H2O2. Data are representative of three
other experiments with different donors. (C) Stimulation of PLD2 with insulin or
mastoparan inhibits ROSI-induced PPAR"-reporter gene expression in a PLD-dependent
manner. CV-1 cells were transfected with ACox–luc together with pcDNA3.1-PPAR$
plasmid and treated for 20 h with 10 %M ROSI, 100 nM insulin, 20 µM mastoparan,
and/or 1.5% 1-BuOH. Luciferase activities are presented as RLU (mean ± SEM, n = 4).
(D) Insulin attenuates PPAR" activation. The ACox-luc reporter alone or in combination
with the PPAR$ plasmid was transfected into B103 cells and exposed to ROSI (5 mM)
alone or with insulin. Reporter gene expression was measured 20h later (n = 5). (E)
CI-PLD2 inhibits insulin-induced CPA production in CV-1 cells. Cells were either
transduced with a CI-PLD2 or an empty adenovirus at MOI of 10. Phospholipids were
biosynthetically labeled using [32P]-orthophosphate for 24 h post-transduction, and the
cells stimulated with 100 nM insulin for 30 min. Phospholipids were separated using
2DTLC and visualized by phosphorimaging. Radioactivity incorporated into the CPA
spot was scraped off and quantified by liquid scintillation counting (cpm mean ± SEM, n
= 3, **p < 0.01). (F) CI-PLD2 acts as a dominant negative and abolishes insulin-induced
inhibition of ROSI-induced PPAR" activation. CV-1 cells were either transduced with an
adCI-PLD2 or an empty adenovirus. Subsequently, the transduced cells were transfected
with the ACox-luc reporter gene and PPAR" plasmids for an additional 24 h. Cells were
stimulated with 10 mM ROSI with or without 100 nM insulin for 20 h, and luciferase
reporter expression determined (mean ± SEM , n=3, **p < 0.01).
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primary human monocytic cells and also in cultured bone marrow-derived mouse and
human peripheral blood mononuclear cells (data not shown) elicited a rapid and
substantial rise CPA level. These results are consistent with the second messenger
properties of CPA; low levels in unstimulated cells, a substantial rise rapidly following
PLD2 stimulation, and deacylation-mediated breakdown (Figure 3-1G).
Another stimulator of PLD2 is mastoparan. Stimulation of PLD2 with mastoparan
or insulin increases CPA production, which in turn should inhibit the transcriptional
activity of PPAR$. To test this hypothesis, CV-1 cells were transfected with PPAR$
reporter plasmids, and exposed to ROSI with and without stimulation with 20 µM
mastoparan or 100 nM insulin (Figure 3-4C). Neither PLD-stimulating agent alone
caused a significant activation in acetyl CoA-oxidase-luciferase (ACox-luc) reporter gene
expression. Rather, mastoparan and insulin both attenuated the ROSI-induced
transcriptional activity of PPAR$. When 1-BuOH was added to the cells to quench
PLD2-mediated CPA production, the inhibitory effect was attenuated, most strongly for
mastoparan (Figure 3-4C). Attenuation of ROSI-induced ACox-luc reporter expression
positively correlated with the concentration of insulin applied (Figure 3-4D).
Insulin stimulates a complex signaling network of which PLD2 activation
represents only one component. To obtain evidence that the PLD2 branch of insulin
signaling is necessary for CPA production, we treated cells with adenoviral (ad)
CI-PLD2, which should abrogate CPA production and the attenuate of PPAR$ activation.
Insulin elicited an increase in the biosynthetically-labeled pool of [32P]-CPA in CV-1
cells; and adCI-PLD2 reduced the insulin-induced generation of [32P]-CPA (Figure
3-4E). We also probed the requirement of PLD2 for insulin-induced inhibition of PPAR$
by using ad CI-PLD2 to attenuate of CPA production in the reporter gene assay.
adCI-PLD2 completely abrogated the inhibitory effect of insulin on PPAR$ (Figure
3-4F). In addition, we knocked down PLD2 expression using a lentivirally-delivered
shRNA against PLD2 in RAW264.7 and NIH3T3-L1 cells (Figure A-3D-F). PLD2
knockdown caused a more than 75% reduction in PMA- and insulin-stimulated CPA 18:1
production in RAW264.7 and 3T3L1 cells (Figure 3-5A and B).
CPA and LPA share similar structure. One concern when treating cells with CPA
is that CPA may activate LPA GPCR receptors directly before it enters cells. B103
neuroblastoma cells, which express barely detectable levels of PPAR$1&2 (Figure 3-5C
inset) and also lack the LPA1/2/3 GPCR (Tsukahara et al., 2006). Hence, B103 cells
represent an ideal cell model for add-back expression of the PPAR$ and PPRE-Acox-luc
reporter. In wild type B103 cells transfected only with the PPRE-Acox-luc reporter ROSI
caused a marginal activation. However, in B103 cells transfected with PPAR" and the
reporter, ROSI- or AGP-induced ACox-luc expression that was inhibited by CPA (5 µM)
and insulin (1 nM) (Figure 3-5C). These observations are consistent with the hypothesis
that CPA is a physiological product of PLD2 and that PLD2-dependent inhibition of
PPAR$ activity is mediated by CPA independently of the LPA1/2/3 GPCR.
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Figure 3-5
responses

CPA production by PLD2 inhibits PPAR$$ -mediated cellular

(A and B) PLD2 knockdown inhibits insulin- and PMA-induced CPA production in
RAW264.7 and 3T3-L1 cells. 3$106 RAW264.7 or NIH3T3 cells expressing scrambled
shRNA or PLD2 shRNA were stimulated with 30 nM insulin or 100 nM PMA for 30 min
prior to extraction of phospholipids for MS analysis (n=3). (C) B103 cells were
transfected with the ACox-luc reporter gene alone or together with the PPAR$ plasmid
and exposed to ROSI (5 mM) with or without CPA (5 mM), AGP (5 mM) and insulin (1
nM) for 20 h, and reporter gene expression measured (mean ± SEM, n = 3). The inset
shows PPAR$ expression in WT B103 cells or cells transfected with the
pcDNA3.1-PPAR$ construct as determined by western blotting. (D) CPA inhibits foam
cell formation and AC-LDL accumulation in the RAW264.7 mouse macrophage cell line.
Cells were stimulated with combinations of 5 mM CPA and ROSI in the presence of 25
mg/ml AC-LDL for 24 h. Lipid accumulation was determined by ORO staining (bar = 50
mm). (E) CPA and the PPAR$ antagonist GW9662 (5 mM each) inhibited ROSI- and
AGP-induced (5 mM each) lipid accumulation in RAW264.7 macrophages. ORO
accumulation was quantifed spectrophotometrically (mean ± SEM, n = 3). The inset
shows PPAR$ expression as assessed by western blotting and the lower panel shows
#-actin as a loading control. (F) CPA inhibition of PPAR$ target gene cd36 activation
requires a PPRE element. CV-1 cells were transfected with PPAR$ together with a cd36
reporter gene containing PPRE at position -273 in the promoter, or a truncated version at
position -261 lacking the PPRE, and were treated for 20 h with 10 mM ROSI, AGP, or
CPA. Luciferase activity was determined, and data are presented as RLU (mean ± SEM,
n = 4).

54

5[
-8QPA\?=G
T>+R!'*(&2

F/
7/
@/
S/
3/
2/
1/

S///
B103

3///

<=>:8?=

'**!+
'**!+

!

!

.;TW?:;

&

!!HI/0/1

50 kDa-

2///

3[3'(1

5[
-8QPA\?=G
T>+R!'*(&2

!!HI/0/1

*D!

!#'(&(

!#'(&()#*!

!#'(&()+,-.

!#'(&()+,-.)#*!

!
!

1///
/

)





&D-,
+,-.
#*!BBB
!4*BBB
.;TW?:;


)





)


)




)





)
)

)







)




)




#*!
#*!)45

+,-.)45

+,-.

456772

!
/0/2

<=>:8?=

/0/3

!@2/;ABCB-$D


)
)






)


**+$)**!+

**+$

$


)


)


!89:;

!
/0/1




)
)

%



)
)


RKQAP?:O=G +(N MLK?G C -$DJ

+=?P9:V=B(:U>9BN;:9TBBCB-$D

@///

6/
X/
F/
7/
@/
S/
3/
2/
1/

*D!

CV-1

#

.;TW?:;
pcDNA3.1 - PPAR 1

<=>:8?=

6
#*!B1XY1BMHAK?ZB1/BB8=??TJ

"

+!527S0F

X/

6
#*!B1XY1BMHAK?ZB1/BB8=??TJ

!

2

!!HI/0/1

'2F3B8G37
'271B8G37

!!HI/0/1

10@

!!

!!

#*!

#*!

1

/0@

/

!#(&(
!4*
+,-.
#*!
456772

E
E
E
E
E

)
E
E
E
E

)
)
E
E
E

)
E
)
E
E

)
E
E
)
E

)
)
E
)
E

)
E
)
)
E

)
E
E
E
)

)
)
E
E
)

)
E
)
E
)

55

/

&D-,

+,-.

!4*

#*!

)B+,-. )B!4*

3.3.5

CPA Inhibits PPAR$$ -Dependent Physiological Responses

We also examined the effect of CPA on PPAR$-regulated lipid accumulation in
RAW 264.7 macrophages after exposure to acetylated low-density lipoprotein
(AC-LDL). Uptake of AC-LDL by unstimulated RAW 264.7 cells was below the
detection limit of the Oil Red O (ORO)-staining (Figure 3-5D). When the AC-LDL was
coapplied with 5 µM ROSI, many ORO-positive macrophages were visible. CPA (5M)
addition to ROSI-stimulated macrophages completely abolished ORO-stained cells,
supporting the hypothesis that CPA inhibits PPAR$-regulated AC-LDL uptake. The
inhibitory effect of CPA on AC-LDL uptake was compared with that of the synthetic
PPAR$ antagonist GW9662 (Figure 3-5E). Both CPA and GW9662 at 5 %M completely
abolished ORO accumulation elicited by either ROSI or AGP in these cells, while
causing no change in the expression of PPAR$ (Figure 3-5E inset). The scavenger
receptor CD36, under direct transcriptional regulation of PPAR$, plays an important role
in the uptake of oxidized phospholipids into macrophages (Boullier et al., 2000). In CV-1
cells, CPA inhibited ROSI- or AGP-activated cd36 reporter gene activation only when
the reporter construct contained an intact PPAR$ response element (PPRE) between
nucleotides -273 to -261 in the promoter (Figure 3-5F). When the cd36 promoter was a
truncated at position -261, neither ligand showed significant modulation of the
expression, which is consistent with the hypothesis that CPA exerts its inhibitory effect
on lipid accumulation via the inhibition of PPAR$ transcriptional targets. PPAR$ is
required for adipocytic differentiation of 3T3-L1 cells (Tzameli et al., 2004). In 3T3-L1
cells, 100 nM ROSI treatment elicits the expression of the adipocytic marker FABP4,
which is a direct target of PPAR$ (Figure 3-6A). CPA treatment caused an
anti-adipogenic effect evident by the reduced expression of FABP4 mRNA, protein, and
by reduced lipid accumulation using ORO staining (Figure 3-6B).
Stimulation with low nanomolar insulin leads to PLD2-dependent CPA formation
that inhibited PPAR$-dependent reporter gene expression (Figure 3-4A-F). To examine
the effects of low-dose insulin on adipocytic differentiation, at concentrations similar to
that found in plasma under fasting conditions (~ 1 nM), 3T3-L1 cells were induced to
differentiate with ROSI for 14 days in the absence or presence of insulin and lipid
accumulation quantified using ORO staining (Figure 3-6C). Continuous low-dose insulin
treatment resulted in the inhibition of adipogenesis as indicated by reduced lipid
accumulation, consistent with the dose-response relationship of insulin-induced inhibition
of PPAR$-reporter gene activation we found in B103 cells (Figure 3-4D). We reasoned
that because PLD2 knockdown in 3T3-L1 cells attenuated insulin-activated CPA
production (Figure 3-5B), it should also reverse the inhibition of PPAR$ target genes
fabp4 and cd36. PLD2 knockdown reversed insulin or mastoparan inhibition of fabp4 and
cd36 expression compared to 3T3-L1 cells transduced with scrambled shRNA (Figure
3-6D and E).
Stimulation of macrophages with ROSI elicits direct activation of
PPAR$-regulated genes (Hodgkinson and Ye, 2003). We selected five PPAR$ target
genes and monitored their transcriptional regulation in mouse peritoneal macrophages
treated with ROSI in combination with CPA or GW9662 for 12h. ROSI stimulation
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Figure 3-6

CPA inhibits PPAR$$ -dependent transcriptional responses

(A) 3T3-L1 cells, which express both PPAR$1 and PPAR$2 protein (western blotting
inset), were pretreated with 1 mM CPA, AGP or vehicle for 24 h and exposed to 100 nM
ROSI. Quantitative RT-PCR (QT-PCR) for the adipocyte marker fabp4 was performed 5
days later. (B) CPA inhibited ROSI-induced lipid accumulation. 3T3-L1 cells pretreated
with 1 mM CPA or vehicle for 24 h were induced to differentiate with ROSI (100 nM
every other day) and stained with ORO after 10 days. Quantification of lipid
accumulation was done spectrophotometrically (n=3). (C) Insulin or CPA inhibited lipid
accumulation in 3T3-L1 cells. Cells were pretreated with 1 mM CPA or vehicle for 24 h
and induced with 100 nM ROSI with or without 1 mM CPA or insulin and stained with
ORO after 2 weeks. Quantification of lipid accumulation was done
spectrophotometrically (n=3, **p=0.0002 for DMSO vs. ROSI, *p=0.0126 for ROSI vs.
ROSI+0.03 nM insulin, **p=0.0010 for ROSI vs. ROSI + 0.3 nM insulin, *p=0.0494 for
ROSI vs. ROSI+1 nM Insulin, and **p=0.0041 for ROSI vs. ROSI+CPA). (D and E)
ROSI-induced gene expression of PPAR$ target genes fabp4 and cd36 is inhibited by
PLD2 in 3T3-L1 cells. 3T3-L1 cells expressing scrambled shRNA or PLD2 shRNA were
pretreated with 30nM insulin or 10mM mastoparan for 30 min and cultured in ROSI (10
%M) or vehicle for 24 h. Total RNA was isolated and mRNA levels determined by
QT-PCR (n=4). (F) Inhibition of ROSI-induced expression of PPAR$ regulated genes by
CPA in mouse peritoneal macrophages. Macrophages isolated from C57BL/6 mice were
exposed to a 5 %M ROSI with or without 5 %M CPA or 1 %M GW9662 (positive control)
for 12 h, and RNA was isolated. mRNA levels for the PPAR$ upregulated (cd36,
cyp27a1, hadh, capn3) and downregulated (csf1) gene targets were determined by
QT-PCR) (n=3, representative experiment shown).
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activated the expression of cd36, cyp27a1, hadh and capn3 by 3- to 4-fold, whereas
inhibited the expression of csf1. CPA as well as GW9662 completely abolished the
transcriptional regulation of these genes by ROSI (Figure 3-6F).
To examine the regulatory role of CPA on a PPAR$-dependent
pathophysiological response we utilized a rodent model of vascular remodeling. ROSI
and AGP induce neointima when applied topically within the carotid artery (Zhang et al.,
2004). Neointima formation requires PPAR$ because it is abolished by the antagonist
GW9662 and is absent in mice with conditional knockout of PPAR$ targeted to cells of
the vessel wall (Cheng et al., 2009). We hypothesized that co-application of CPA with
the PPAR$ agonists AGP or ROSI should mitigate neointimal thickening. AGP or ROSI
with or without CPA was injected lumenally into the common carotid artery of rats,
which had been transiently ligated proximally and distally from the carotid glomus. After
a 1 h treatment, the cannula was withdrawn and blood flow through the common carotid
artery restored. Histological evaluation of the dissected common carotid arteries 3 weeks
later revealed multilayered neointimal thickening in the rats treated with 5 %M AGP
(Figure 3-7A) or ROSI (Figure A-4B) whereas, no neointima was found in the
solvent-treated carotids (Figure A-4A). The neointimal thickening was abolished in those
animals that received 5 %M CPA in addition to AGP or ROSI (Figure 3-7B and C, Figure
A-4C and D). Our experiments identified insulin as a physiologically relevant stimulator
of CPA production. Therefore, endogenous production of CPA activated by low
concentrations of insulin should prevent neointima formation in this model. To test this
possibility, we co-applied 3 nM insulin with 10 µM AGP or ROSI lumenally for 1 h
using the same experimental paradigm described for the application of CPA. Examination
of the intima-to-media ratio three weeks later showed that low-dose insulin treatment
alone induced no vascular remodeling, but insulin co-treatment significantly reduced the
neointima formation elicited by AGP or ROSI (Figure 3-4E-G, Figure 3-7D-F). These
results are consistent with the hypothesis that exogenously applied or endogenously
generated CPA is effective in negatively modulating PPAR$-dependent vascular wall
responses in vivo.
3.4

DISCUSSION

The present findings provide evidence that CPA is a bona fide second messenger
and a negative physiological regulator of PPAR$. CPA is a high-affinity ligand of PPAR$
with an apparent Kd in the hundred-nanomolar range, comparable to that of TZDs. CPA
binds to a site within the LBD that prevents activation by three different TZD compounds
and the endogenous phospholipid agonist AGP, and it stabilizes binding of the
corepressor SMRT. CPA lacks the ability to activate PPAR$ due to its cyclic phosphate
moiety. In contrast, AGP and LPA both possess a free phosphate and are agonists of
PPAR$ (Tsukahara et al., 2006). CPA is barely detectable in resting cells but is generated
intracellularly in a stimulus-coupled manner by PLD2 and is then degraded by
phospholipase(s) or acyltransferase(s) via deacylation. PLD2 is the target and
convergence point of several receptor-coupled signal transduction pathways (Huang and
Frohman, 2007) suggesting that PPAR$ is modulated by stimuli of this enzyme. The
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*p < 0.05

AGP
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CPA and insulin prevent carotid wall remodeling

(A-C) Carotid arteries of anesthetized adult rats (5 per group) were exposed to 5 %M
AGP alone (A) or with 5 %M CPA (B) for 1 h. (Masson trichrome staining, bar 200 µm).
(C) CPA treatment blocks increase in intima-to-media ratios AGP-induced rat carotid
arteries (n=5 per group). (D-F) Insulin (3 nM) was applied alone (D) or with 5 %M AGP
(E) intralumenally for 1 h and neointima formation assessed three weeks alters. Bar
represents 200 %m. (F) Quantification of intima/media ratios (n=5).
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present findings establish that PLD2 can produce at least two second messengers, PA
from the hydrolysis of phosphatidylcholine and CPA from LPC, depending on substrate
availability. The availability of LPC is likely to be regulated by activation of
phospholipases A2, which are concomitantly activated by the same stimuli that activate
PLD2 (Kim et al., 1999). Physiological stimuli of PLD2 can generate CPA in biologically
effective concentrations, as indicated by our findings using the foam-cell formation and
adipocyte differentiation models in cultured cell lines and also using primary
monocytes/macrophages, and PPAR$-dependent vascular remodeling in vivo. In addition,
the present data reinforce the long-standing observation that low concentrations of insulin
protect against neointimal growth (Breen et al., 2009).
Current paradigms for PPAR$ signaling do not take into consideration the
possibility of endogenous negative regulators fine-tuning, and under certain conditions
even abrogating the cellular responses mediated through this nuclear hormone receptor.
Our findings challenge this view by identifying CPA as an endogenous negative regulator
of PPAR$. Individual variations in patients in the activation of the PLD2-CPA axis are
likely to modulate therapeutic responses to the widely used class of TZD drugs targeting
PPAR$. Hence, the present results provide new grounds for rethinking our current
concepts governing the regulation of this nuclear hormone receptor and raise the
possibility of utilizing this phospholipid scaffold as a lead for the synthesis of novel
medicines acting on PPAR$.
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CHAPTER 4.

REGULATION OF NUCLEAR HORMONE RECEPTOR PPAR$
BY ENDOGENOUS LYSOPHOSPHATIDIC ACIDS*
4.1

4.1.1

INTRODUCTION

Lysophosphatidic Acid (LPA) in the Vasculature

LPA has been identified as a bioactive lipid and is produced in serum after the
activation of multiple biochemical pathways linked to platelet activation (Sano et al.,
2002, Spector, 2003, Tigyi and Parrill, 2003, Bolen et al., 2011). The concentration of
LPA in plasma is in the nanomolar range, whereas it can reach concentrations as high as
10 %M in serum during blood clotting (Baker et al., 2001, Aoki et al., 2002, Baker et al.,
2002). LPA production in blood requires autotaxin (ATX), which is a secreted
lysophospholipase D that generates LPA from lysophosphatidylcholine (LPC) (Tokumura
et al., 2002, Umezu-Goto et al., 2002).
LPA plays an important role in vascular development (van Meeteren et al., 2006).
ATX-deficient mice die at approximately embryonic day 9.5 with severe vascular
formation defects in the yolk sac and enlarged embryonic blood vessels (Tanaka et al.,
2006, van Meeteren et al., 2006). Mice that overexpress ATX have elevated plasma LPA
levels and show bleeding diathesis, whereas ATX+/- heterozygous mice have almost half
the plasma LPA levels and are prone to thrombosis (Pamuklar et al., 2009).
LPA promotes proliferation and migration of vascular smooth muscle cells
(VSMCs) (Hayashi et al., 2001, Siess, 2002, Kim et al., 2006). LPA increases endothelial
permeability (Schulze et al., 1997, Alexander et al., 1998, van Nieuw Amerongen et al.,
2000) and induces E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and vascular
endothelial growth factor-C (VEGF-C) expression in human endothelial cells (Rizza et
al., 1999, Lin et al., 2008). Hayashi et al. reported that LPA promotes VSMC
dedifferentiation from the contractile phenotype to a secretory phenotype and stimulates
VSMC signaling pathways in vitro (Hayashi et al., 2001).
Many of the cellular responses elicited by LPA, including platelet activation
(Siess et al., 1999, Rother et al., 2003, Haseruck et al., 2004), endothelial cell activation
(Siess et al., 1999), proliferation, migration, and phenotypic modulation of VSMCs
(Hayashi et al., 2001, Siess, 2002, Kim et al., 2006), are all involved in neointima
formation. Oxidative modification of low-density lipoprotein (LDL) is considered to be
an early event in arterial wall remodeling leading to atherosclerosis (Stocker and Keaney,
2004, Asmis et al., 2005); and uptake and oxidation of LDL in the arterial wall is an
important mechanism in the pathogenesis of atherosclerosis (Meydani, 2001). It has been
* Adapted with permission. Tsukahara R, Tsukahahara T, Tigyi G (2011) Regulation of
the nuclear hormone receptor PPARgamma by endogenous lysophosphatidic acids. In:
Lysophospholipid receptors: Signaling and biochemistry, in press. NJ: Wiley.
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shown that LPA is formed during mild oxidation of LDL (mox-LDL)(Siess et al., 1999,
Law et al., 2000). In addition, the lipid-rich core of human atherosclerotic plaques, which
accumulates oxidized lipids including mox-LDL, contains several species of acyl-LPA
and AGP (Siess et al., 1999). Acyl-LPA and AGP accumulated in human atherosclerotic
plaques are likely to activate platelets and initiate thrombus formation upon plaque
rupture (Rother et al., 2003, Spector, 2003). Following plaque rupture, LPA becomes
available to circulating platelets, initiating activation, which in turn may contribute to the
induction of thrombosis, leading to myocardial infarction and stroke. A clinical study has
shown that the serum LPA level is significantly elevated in patients with acute
myocardial infarction (Chen et al., 2003).
4.1.2

Neointima Formation Induced by LPA

Atherosclerosis is the leading cause of death and serious morbidity in developed
countries. Neointimal lesions are characterized by accumulation of cells within the
arterial wall and are an initial step in the pathogenesis of atherosclerosis, which leads to
the ischemic syndromes of heart and stroke (Ross, 1999, Baim et al., 2002).
Yoshida et al. first reported that LPA species containing unsaturated fatty acyl
groups 16:1, 18:1, and 18:2 induced neointima formation when injected intralumenally
into the rat carotid artery, whereas saturated acyl-LPA species such as 16:0 and 18:0 were
inactive (Yoshida et al., 2003). This model comes close to the pathophysiological
response seen in humans when mechanical injury is not the cause of the arterial wall
remodeling leading to neointimal lesions. In Yoshida's model, LPA was injected through
the external carotid artery into a ligated section of the common carotid artery (CCA) that
was rinsed free of blood and maintained close to the mean arterial perfusion pressure.
There was no mechanical injury or removal of endothelial cells in the CCA. A brief
one-hour exposure to unsaturated but not to saturated species of LPA caused neointima
development. Our group found that the LPA-elicited neointima was not mediated by the
LPA G protein-coupled receptors (GPCRs) LPA1 and LPA2, which are the major LPA
receptor subtypes expressed in the vessel wall (Cheng et al., 2009). A peroxisome
proliferator-activating receptor " (PPAR")-specific inhibitor, GW9662, abolished the
LPA-induced neointima formation, suggesting that arterial wall remodeling elicited by
LPA is a PPAR"-mediated response (Zhang et al., 2004). Conversely, the
PPAR"-specific agonist rosiglitazone (ROSI; Figure 4-1) also elicited neointima
formation in the same model. Genetic evidence also supports the role of PPAR" in
arterial wall remodeling. When conditional knockout PPAR$-/- mice with this receptor
knocked out in the endothelial cells, VSMCs, and cells of the macrophage/monocyte
lineage were exposed to AGP (Figure 4-1) or ROSI, neither agent elicited neointima
formation or vascular wall remodeling (Cheng et al., 2009). It is important to note that in
a carotid injury model, ROSI diminished the size of the neointima. The opposite effect of
ROSI and LPA in these two different models indicates differences in the mechanism
underlying vascular wall remodeling in the two models (Cheng et al., 2009). These
results, combined with the observation that GW9662 abolished neointima in response to
ROSI or AGP (Zhang et al., 2004), suggest that PPAR$ is required for LPA-induced
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neointima formation in the absence of vascular wall injury.
Subramanian et al. reported that LPA1 and LPA3 GPCRs play an important role in
neointima formation (Subramanian et al., 2010). Using a wire-injury model, these authors
showed that neointima formation was inhibited by the LPA1 and LPA3 inhibitor Ki16425
and that vascular wall remodeling induced by LPA was inhibited by short-term
knockdown of either LPA1 or LPA3 with siRNA (Subramanian et al., 2010). In sharp
contrast with the findings of Subramanian et al., LPA1-/- mice in our non-injury model
develop neointimal in response to AGP stimulation. Moreover, although LPA1 and LPA3
GPCRs are respectively 12 and 100 times less sensitive to AGP than LPA (Fujiwara et
al., 2005), AGP is more potent than LPA in inducing neointima formation (Zhang et al.,
2004). They also observed that Mac-2 positive cells were accumulated in the neointimal
area after vascular injury (Subramanian et al., 2010); in contrast, our non-injury model
showed few macrophages in the neointimal region induced by AGP or ROSI (Cheng et
al., 2009), suggesting that the cellular elements leading to neointima formation are
different between the two models.
Although some clinical studies in diabetic patients have shown a reduction in
carotid artery wall thickness after treatment with thiazolidinediones (TZDs)
(Minamikawa et al., 1998, Haffner et al., 2002), other studies suggested that ROSI
increases the risk of myocardial infarction and death from cardiovascular causes
(Goldberg et al., 2005, Nissen and Wolski, 2007, 2010), indicating that TZD therapy may
actually increase the risk of cardiovascular events. Moreover, in 2010, the U.S. Food and
Drug Administration restricted use of ROSI to patients with type 2 diabetes due to the
potential for cardiovascular ischemic risks, including heart attack.
4.1.3

PPAR$$ – an Intracellular LPA Receptor

Only unsaturated acyl-LPA species induce neointima formation; saturated
acyl-LPA species are inactive (Yoshida et al., 2003, Zhang et al., 2004) indicating the
need for an unsaturated fatty acid in the activation of the mechanism that underlies the
formation of neointima. The structure-activity relationship of neointima induction by
LPA does not match that of the known LPA GPCRs because saturated LPA species
activate the LPA GPCRs (Zhang et al., 2004, Fujiwara et al., 2005). However, the
structure-activity relationship of PPAR" activation by LPA species matches that of the
neointima response in vivo (Zhang et al., 2004). ROSI and the unsaturated acyl-LPA
species all activate the peroxisome activator response element-contianing
acyl-coenzyme A oxidase-luciferase (PPRE-Acox-Luc) reporter construct, whereas all
saturated species, 2,3-cyclic phosphatidic acid (CPA) (Figure 4-1), and the related lipid
mediator sphingosine-1-phosphate were inactive (Tsukahara et al., 2006).
PPARs are members of the nuclear hormone receptor superfamily, many of which
function as lipid-activated transcription factors (Tontonoz and Spiegelman, 2008). There
are three types of PPAR; PPAR!, #/", and $. PPAR$, the most extensively studied among
the three PPAR subtypes, plays an important role in regulating lipid metabolism, glucose
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homeostasis, cell differentiation, and motility (Duval et al., 2002, Evans, 2005,
Kiec-Wilk et al., 2005). PPAR$ has two isoforms, PPAR$1 and $2. PPAR$2 differs from
PPAR$1 only by 30 additional amino acids at the N-terminus, caused by differential
promoter usage and alternative splicing (Fajas et al., 1997). PPAR$1 is expressed
ubiquitously in almost all tissues, whereas PPAR$2 is highly expressed in only in the
adipose tissue (Lehrke and Lazar, 2005). Genetic deletion of PPAR$1 causes embryonic
mortality (Asami-Miyagishi et al., 2004). In contrast, deletion of PPAR$2 causes minimal
alterations in lipid metabolism (Medina-Gomez et al., 2005). PPAR$ heterodimerizes
with the retinoid X receptor # (RXR#), and it is the ligand binding domain (LBD) of
PPAR$ that interacts with its agonists, including LPA (Weatherman et al., 1999). The
PPAR"-RXR# heterodimer binds the peroxisome proliferator response element (PPRE)
in the promoter region of the target genes. In the absence of ligands, the corepressors
NCoR and SMRT (Chen and Evans, 1995, Dowell et al., 1999, Yu et al., 2005) bind to
the heterodimer to suppress the target gene activation. Upon ligand binding, PPAR$
undergoes a conformational change that facilitates the dissociation of the corepressors
and recruits the p300 coactivator and the PGC-1! coactivator (Nolte et al., 1998, Yu and
Reddy, 2007), resulting in target gene transcription (Lala et al., 1996).
A number of putative physiological agonists of PPAR$ have been identified,
including 15d-PGJ2 (Forman et al., 1995), oxidatively modified fatty acids (Nagy et al.,
1998, Baker et al., 2005, Li et al., 2008), select species of LPA and AGP (McIntyre et al.,
2003, Zhang et al., 2004, Tsukahara et al., 2006), oxidized phospholipids (Davies et al.,
2001), and nitrated fatty acids (Li et al., 2008). Among these ligands, AGP stands out
with an equilibrium binding constant of 60 nM (Tsukahara et al., 2006) that is similar to
that of the TZD class of synthetic agonists. The TZD class of antidiabetics, including
ROSI, pioglitazone, and troglitazone, are full agonists of PPAR$ and have been clinically
used to improve insulin sensitivity and lipid metabolism in type 2 diabetics (Froberg and
Andersen, 2005, Lautamaki et al., 2005, Negro et al., 2005, Sarafidis et al., 2005).
However, despite the beneficial effects of PPAR$ on glucose and lipid
homeostasis, excessive PPAR$ activity can be deleterious. PPAR$ agonists promote
adipocytic differentiation of 3T3-L1 cells and also stimulate the uptake of LDL by
macrophages, leading to foam cell formation in the arterial wall (Moore et al., 2001). Our
results suggest that LPA-mediated activation of PPAR$ can also contribute to vascular
wall pathologies.
PPAR$ plays an important role in the cardiovascular system. PPAR$ is expressed
in all cell types of the vessel wall (Marx et al., 1998, Delerive et al., 1999, Rangwala and
Lazar, 2004), as well as in monocytes and macrophages (Tontonoz et al., 1998). PPAR$
expression is upregulated in VSMCs (Law et al., 2000), endothelial cells (Delerive et al.,
1999), and macrophages (Tontonoz et al., 1998) in human atherosclerotic plaques and
neointimal lesions. PPAR$ expression is also elevated in neointimal lesions after
mechanical injury to the endothelium (Law et al., 2000). ROSI suppresses neointima
formation after endothelial injury in rats (Lim et al., 2006). On the other hand, in our
non-injury model, ROSI induces neointima formation when intraluminally applied into
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carotid arteries (Zhang et al., 2004, Cheng et al., 2009). Thus, the mechanisms underlying
neointima formation in the chemically induced neointima model are likely to be different
from those in the non-injury induced neointima models.
4.1.4

2,3-Cyclic Phosphatidic Acid (CPA) – an Endogenous Antagonist of PPAR$$

CPA, an analog of LPA with a five-atom ring linking the phosphate to two of the
glycerol carbons (Figure 4-1), is found in diverse organisms from slime mold to humans
(Murakami-Murofushi et al., 2000); its functions are largely unknown. The concentration
of CPA in human serum is estimated to be ~0.01 %M, 10-fold lower than that of LPA
(Eichholtz et al., 1993, Kobayashi et al., 1999). Although CPA is structurally similar to
LPA, CPA shows several unique actions compared to LPA. CPA inhibits cell
proliferation (Fischer et al., 1998), induces actin stress fiber formation (Fischer et al.,
1998), promotes differentiation and survival of cultured embryonic hippocampal neurons
(Fujiwara et al., 2003), inhibits LPA-induced platelet aggregation (Gueguen et al., 1999),
and suppresses cancer cell invasion and metastasis in vitro and in vivo (Mukai et al.,
1999, Ishihara et al., 2004, Uchiyama et al., 2007). Our group showed that CPA
negatively regulates PPAR$ functions by stabilizing the SMRT-PPAR$ complex
(Tsukahara et al., 2010). Furthermore, we showed that CPA is generated intracellularly
by phospholipase D2 (PLD2) (Tsukahara et al., 2010).
5-Fluoro-2-indolyl des-chlorohalopemide (FIPI) is an inhibitor of both PLD1 and PLD2
isozymes (Su et al., 2009). FIPI inhibits PLD2-mediated CPA production in human
peripheral mononuclear cells stimulated with LPS (Tsukahara et al., 2010). We also
demonstrated that activation of PLD2-mediated CPA production or topical application of
CPA together with PPAR$ agonists prevents neointima formation, adipocytic
differentiation, lipid accumulation, and the upregulation of PPAR$ target gene
transcription in mouse macrophages (Tsukahara et al., 2010). These findings support our
hypothesis that CPA is an endogenous antagonist of PPAR$.
In the following material, we describe some of the fundamental methodologies
that we and others have used in probing the actions of LPA and CPA on PPAR$ in vitro
and in vivo.
4.2
4.2.1

METHODS PROBING PPAR$$ FUNCTION WITH LPA

Reporter Gene Assay for Ligand Activation of PPAR!

The reporter gene assay is a sensitive method of monitoring ligand-induced gene
expression. The determination of PPAR" activation in cells transiently transfected with
the PPRE-ACox-Luc or TK-MH100-Luc reporter gene construct has been reported
previously (Tsukahara et al., 2006, Tsukahara et al., 2010) (Figure 4-2A and B). We used
the B103 rat neuroblastoma cell line because this cell line lacks LPA GPCRs LPA1, LPA2
and LPA3 and expresses very low levels of endogenous PPAR$, making it an ideal
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(A and B) Schematic diagram of reporter gene assay using PPAR" and its reporter
plasmid. PPAR" agonists induce luciferase transcription, whereas PPAR" antagonist
inhibits PPAR" agonist-induced reporter gene transcription. (C) CPA suppresses
ROSI-induced PPAR"-dependent reporter gene activation in B103 cells. B103 cells
(3$104) were transfected with reporter plasmid (PPRE-ACox-Luc or TK-MH100-Luc),
pcDNA3.1-PPAR" or pCMX-Gal4-PPAR", and SV40-!-galactosidase. After
transfection, the cells were exposed to 10%M CPA with or without ROSI (10 %M) for 20
h, and luciferase activities were measured. Data represent mean ± SEM; n = 4.
68

low-background cell type for transfection studies. B103 cells, 3.0$104 per well, were
plated to 96-well plates the day before transfection. Using LipofectAMINE 2000, the
cells were transfected with 125 ng of the reporter plasmid (PPRE-ACox-Luc or
TK-MH100-Luc), 62.5 ng of pcDNA3.1-PPAR" or pCMX-Gal4-PPAR", and 12.5 ng of
SV40-!-galactosidase (Promega), the latter to monitor transfection efficiency. Twenty
hours posttransfection, 10 µM ROSI (Figure 4-1) (ALEXIS Biochemicals), 10 µM AGP
18:1, or 10 µM CPA 18:1 (Avanti Polar Lipids) dissolved in 1% Me2SO and mixed with
Opti-MEM I (Invitrogen) and 1% fetal bovine serum (HyClone) were applied for 20 h at
37°C in the presence of 5% CO2. Luciferase and !-galactosidase activities were measured
with the Steady-Glo luciferase assay system (Promega) and the Galacto-Light Plus
system (Applied Biosystems), respectively. Samples were run in quadruplicate, and the
means ± S.E. were calculated. Representative data are shown in Figure 4-2C.
4.2.2 Competition Ligand Binding of PPAR! Using ROSI/AGP against
LPA/AGP/CPA
PPAR" consists of a ligand binding domain (LBD) and a DNA binding domain
(DBD) (Figure 4-3). To test whether LPA/AGP/CPA interacts with the PPAR" LBD,
competition ligand binding assays were performed (Figure 4-4A). Hexahistidine (His6)
epitope-tagged PPAR" LBD fusion proteins or empty vector controls containing the His6
and thrombin recognition site can be expressed in BL-21 (DE3) E. coli cells (Invitrogen).
Transformed BL-21 cells were induced using 0.3 mM isopropyl 1-!-D-galactopyranoside
(Fisher Scientific) for 12 h at 25°C and collected by centrifugation. The PPAR" LBD was
extracted with lysis buffer (50 mM HEPES-KOH, pH 6.8, 200 mM NaCl, 5 mM DTT, 1
mM phenylmethanesulfonyl fluoride, 0.5% Triton X-100, and 15% glycerol) and
centrifuged at 12,000 $ g for 20 min. Supernatant (1 ml) was incubated with 50 µl of
TALON metal affinity resin (BD Biosciences) at 4°C for 1 h in the lysis buffer. The resin
was washed five times with wash buffer (50 mM HEPES-KOH, pH 6.8, 200 mM NaCl, 5
mM DTT, 15% glycerol, and 5 mM imidazole) and eluted with 150 mM imidazole in
wash buffer. The purity of the PPAR" LBD was determined using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis followed by Coomassie Blue staining and
western blot analysis using a PPAR" antibody (sc-7196; Santa Cruz Biotechnology). For
the equilibrium binding assay, 1 µg of His6-PPAR" LBD fusion protein (Figure 4-4A)
was incubated in binding buffer (50 mM HEPES, pH 6.8, 100 mM NaCl, 5 mM EDTA,
and 5 mM DTT) in the presence of 5 nM [3H]ROSI (American Radiolabeled Chemicals)
or [32P]AGP at 18°C for 1 h. [32P]AGP 18:1 was synthesized from
1-O-octadecenyl-sn-glycerol 18:1 using recombinant 1,2-diacylglycerol kinase
(Calbiochem). 1-O-octadecenyl-sn-glycerol 18:1 was solubilized in 20 µl of an
octyl-!-glucoside/cardiolipin solution (7.5% octyl-!-glucoside and 5 mM cardiolipin in
0.5% Triton X-100) by sonication in a bath sonicator (Branson) for 30 s. To the
solubilized 1-O-octadecenyl-sn-glycerol 18:1/octyl-!-glucoside/cardiolipin solution was
added 50 µl of reaction buffer (100 mM imidazole HCl, pH 6.6, 100 mM NaCl, 25 mM
MgCl2, and 2 mM EGTA), 2 µl of 100 mM DTT (freshly prepared), 10 µl of diluted 1,2diacylglycerol kinase, and water to a total volume of 90 µl. The reaction was started by
the addition of 10 µl of ["-32P]ATP (PerkinElmer; 10 mCi/ml; specific activity,
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Figure 4-3

The structures of PPAR!1 and PPAR !2

Human PPAR"1 and PPAR "2 proteins are 53 and 57 kDa, respectively. The two PPAR"
isoforms differ only 30 amino acids at the N-terminal end. Domain C and E represent
DNA binding domain (DBD) and ligand binding domain (LBD), respectively.
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determined using 2.5 %M cold ROSI, LPA18:1, or CPA. Data are mean ± SEM; **p <
0.01.
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111TBq/nmol) and incubated at 25°C for 1 h.
Lipids were extracted by a modification of the method of Bligh and Dyer (Bligh
and Dyer, 1959). NaCl (1 M) was added to bring the aqueous volume to 0.8 ml. Total
lipid was extracted with 3 ml of chloroform/methanol (1:2, v/v). Then, 1 ml of
chloroform and 1 ml of 1 M NaCl were added and phase separated by centrifugation
(3,000 $ g, 5 min). The lower phase was collected and dried under nitrogen. This was
dissolved in 50 µl of chloroform/methanol (1:2, v/v) and was spotted on a Silica Gel 60
(Merck) thin layer chromatography plate. Plates were developed with
chloroform/methanol/acetic acid (65:15:5, v/v) and subjected to radioautography. The
radioactive spot corresponding to AGP 18:1 was scraped into a scintillation vial.
Counting was carried out in an LS-6500 Beckman scintillation counter. The radioligand
bound to the PPAR" LBD fusion protein was precipitated using 36% (w/v) polyethylene
glycol 8000 (Fisher Scientific) in the presence of 3.3% (w/v) "-globulin (Sigma-Aldrich),
collected on DEAE-81 filter disks (Whatman), and quantified by liquid scintillation
counting. Nonspecific binding was determined in the presence of nonradioactive 10 %M
AGP. For competition binding assays, 1 µg of His6-PPAR" LBD protein was incubated at
18°C for 1 h in 200 µl of binding buffer in the presence of 5 nM [3H]ROSI or 5 nM
[32P]AGP with or without 2.5 %M cold compounds. The radioactive ligand-bound
His6-PPAR" LBD was collected on DEAE-81 filter disks. The disks were washed three
times with wash buffer (50 mM HEPES, pH 6.8, 100 mM NaCl, 5 mM DTT), and bound
radioactivity was quantified by scintillation counting. An example of LPA and CPA
competition with [3H]ROSI binding is shown in Figure 4-4B.
4.2.3

Corepressor Mammalian Cell Two-Hybrid Assay

This assay was performed to test the effect of CPA on SMRT corepressor binding
to PPAR" (Figure 4-5A). CV-1 cells (African green monkey kidney cell line) were grown
in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum
(FBS) supplemented with 100 IU/ml penicillin G and 100 %g/ml streptomycin at 37°C in
a humidified 5% CO2 atmosphere. The cells were plated onto 96-well plate at the density
of 1.0 $ 104 cells per well in DMEM containing 10% FBS. The next day, the cells were
transiently transfected with 71 ng UAS-Luc, 14.3 ng Gal4-SMRT, 14.3 ng
pVP16-PPAR"2, and 10 ng pSV-!-galactosidase (Promega) using Lipofectamine LTX
(Invitrogen) and Opti-MEM (Invitrogen) for 20 h. After 20 h transfection, the cells were
pretreated with 10 nM, 100 nM, 1 %M, and 10 %M of CPA 18:1 or
cyclic glycerophosphate (CGP, Figure 4-1; Avanti Polar Lipids), which is the alkyl ether
analog of CPA 18:1, for 30 min, followed by treatment with 1 nM ROSI for 6 h.
Luciferase and !-galactosidase activities were measured with the Steady-Glo luciferase
assay system (Promega) and the Galacto-Light Plus system (Applied Biosystems),
respectively. Samples were run in quintuplicate, and the mean ± SEM were calculated.
The data shown in Figure 4-5B are representative of at least three independent
transfections. As shown in Figure 4-5B, CPA 18:1 and its ether analog CGP 18:1 dose
dependently stabilized the PPAR$-SMRT complex and prevented ROSI-induced
dissociation of the complex (*p < 0.05; **p < 0.01).
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4.2.4 Non-Injury Infusion Model Using Rat Carotid Arteries to Elicit Neointima
Formation
To examine the regulatory role of CPA in PPAR$-dependent pathophysiological
responses, a rat non-injury infusion model was used. The animal procedures were
approved by the Institutional Animal Care and Use Committee of the University of
Tennessee Health Science Center. Adult male Sprague-Dawley rats weighing 250-300 g
were anesthetized with ketamine (80 mg/kg) and xylazine (5 mg/kg). After anesthesia,
the forelimbs and incisors were fixed to the surgical board with tape. The hair around the
neck was shaved, and the skin was disinfected with povidone-iodine and 70%
isopropyl alcohol. The surgery was carried out under a dissecting microscope. The right
side of the carotid artery was surgically exposed through a midline incision. The proximal
sides of the common carotid artery (CCA) and internal carotid artery (ICA) were ligated
using vessel clips (85 gr. pressure, BRI). The distal end of the external carotid artery
(ECA) was tied with 5.0 surgical suture (Harvard); subsequently, another 5.0 surgical
suture was passed through the proximal end of the ECA and a loose loop was made. A
PE-10 catheter (Becton Dickinson) was connected to a servo-controlled peristaltic pump
(Model PS-200; Living Systems Instrumentation (ST.Albans, VT)) to maintain the
intraarterial pressure at 100 mm Hg. The other end of the PE-10 catheter was inserted
into the ECA through arteriotomy without mechanical injury to the CCA. The loose loop
was tightened on the ECA to keep the catheter in place. The clip occluding the CCA was
temporarily released, and the vessel was rinsed with a retrograde injection of 50 %l of
phosphate-buffered saline (PBS) to remove residual blood. The CCA was clipped again,
and a treatment solution either 0.1% DMSO (vehicle), 10 %M AGP, 10 %M ROSI, 10 %M
PIO, 10 nM insulin, 750 nM FIPI, or the combination of these compounds was applied.
The delivery pressure of the solutions was maintained at 100 mm Hg using the peristaltic
pump.
In some experiments, ROSI was applied outside the carotid artery in a pluronic
gel. Pluronic F-127 (Sigma-Aldrich) was dissolved in PBS (25% w/v) and maintained at
4°C until use. At the time of compound administration via the PE-10 catheter, 100 %l of
the pluronic gel containing 100 %M ROSI and 0.1% DMSO was topically applied around
the adventitia of the CCA for 1 h. The control group received the pluronic gel without
ROSI.
For cotreatment with FIPI, the inhibitor was applied for 30 min as a pretreatment
and also included during the application of the PPAR" agonists. After a 60-min
incubation, the ligation was loosened to withdraw the catheter and the loop was tied up
again to ligate the ECA. The vessel clips on the CCA and ICA were released to restore
blood flow. The wound was closed with 4.0 surgical suture. After the surgery, the rats
were kept on a warming pad to avoid hypothermia during recovery and were
administered Buprenex (0.05 mg/kg). Three weeks after the surgery, transcardial
perfusion was performed with 4% buffered paraformaldehyde (pH 7.4), and the CCAs
were dissected and postfixed in 4% buffered paraformaldehyde (pH 7.4). The dissected
CCAs were embedded in paraffin; and 5-%m thick sections were cut, deparaffinized, and
stained with Masson’s trichrome stain (Allan Scientific). Neointima formation was
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observed under a light microscope. To evaluate neointima progression, the
intima-to-media ratio was used. The intima (area between the endothelium and the
internal elastic lamina) and media (area between the external and internal elastic lamina)
were measured using ImageJ software (version 1.42), and intima-to-media ratios were
calculated.
As shown in Figure 4-6 (unpublished data), neointima formation induced by AGP
was attenuated by insulin due to the production of CPA through PLD2 activation by
insulin (Figure 4-6B, C, and E) (Tsukahara et al., 2010). This insulin effect was blocked
by the PLD inhibitor FIPI because the CPA production was not sufficient due to the
inhibition of PLD2 activity (Figure 4-6D and E).
Pioglitazone induced arterial wall remodeling; the magnitude, however, was
significantly less than that induced by ROSI (Figure 4-7 B, C, and E) (unpublished data).
This might be one of the reasons that ROSI shows higher cardiovascular risks. ROSI
applied to the outside of CCAs with pluronic gel also induced neointima formation
(Figure 4-7D and E), suggesting that ROSI diffused toward the inside of the vessel and
promoted arterial wall thickness.
4.2.5

Immunohistochemical Staining

It has been implicated that bone marrow-derived vascular progenitor cells (VPCs)
can contribute to neointima formation (Saiura et al., 2001, Zernecke et al., 2005). To
assess whether VPCs are recruited to form neointima in response to AGP or ROSI
treatment in the non-injury model, immunohistochemical analysis was performed using
antibodies to the VSMC marker !SMA and the VPC marker CD133. Five-%m thick cross
sections of the rat CCAs were double-stained for !SMA and CD133 to identify VPCs in
the neointimal regions. After deparaffinization and rehydration, heat-mediated antigen
retrieval was carried out using citrate-based antigen unmasking solution (Vector
Laboratories) for 10 min on formalin-fixed tissue slides. After three washes in PBS (pH
7.4), the slides were blocked with blocking solution containing 5% normal goat serum
(Vector Laboratories) and 5% normal horse serum (Vector Laboratories) in PBS for 1 h
at room temperature. !SMA antibody (mouse monoclonal [clone 1A4], 1:400 dilution;
Abcam) and CD133 (rabbit polyclonal [ab19898], 1:100 dilution; Abcam) diluted in
blocking solution were applied to the slides and incubated overnight at 4°C. The slides
were incubated with fluorescein-conjugated horse anti-mouse IgG (1:200 dilution; Vector
Laboratories) secondary antibody or biotinylated goat anti-rabbit IgG (1:500 dilution;
Vector Laboratories) secondary antibody dissolved in blocking solution for 30 min,
followed by incubation with rhodamine-avidin D (1:1000; Vector Laboratories) for 30
min at room temperature after washes with PBS. The slides were mounted with
VECTASHIELD with DAPI (Vector Laboratories) and visualized with a Nikon Eclipse
80i fluorescence microscope.
DMSO-treated CCA showed no CD133-positive cells (Figure 4-8B); however,
anti-CD133 staining showed positive cells in the neointimal region (Figure 4-8E), and
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Figure 4-6
PLD inhibitor FIPI inhibits physiological insulin effect on vascular
wall remodeling
(A-D) Carotid arteries of anesthetized adult rats were treated with DMSO (vehicle) (A),
10 %M AGP (B), 10 %M AGP and 10 nM insulin (C), or 10 %M AGP, 10 nM insulin, and
750 nM FIPI(D) for 1h. Three weeks after the treatment, the CCAs were dissected and
the sections were stained with Masson’s trichrome stain. Scale bars represent 200 %m. (E)
Quantification of intima/media ratios. Data are mean ± SEM; n=5.
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Figure 4-7
PIO induces less neointima and ROSI application from the outside
also induces arterial wall thickness
(A-D) Carotid arteries of anesthetized adult rats were transfused with vehicle (A), 10%M
PIO (B), or 10 %M ROSI (C) for 1h. 100 %M ROSI was applied to the outside of vessel
using 25% pluronic gel for 1h (D). The sections were stained with Masson’s trichrome
stain. Scale bars represent 200 %m. (E) Quantification of intima/media ratios. Data are
mean ± SEM; n=5.
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Figure 4-8
Immunohistochemical staining for ! SMA and CD133 in the
neointima induced by AGP
Rat carotid arteries treated with DMSO (A-C) and 10 %M AGP (D-F) were
double-stained for !SMA (green; A and D) and CD133 (red; B and E). The cells were
intensively stained with anti-!SMA in the media and neointima layers (A and D).
Anti- CD133 stained cells were barely seen (B), however, CD133 positive cells were
accumulated in neointima region (E). Double stained cells were seen in the merged image
(F). Area between the white arrows is neointima (D-F). Scale bars: 200 %m.
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CD133-positive cells were also expressed !SMA (Figure 4-8F).
4.3

SUMMARY

In this chapter, we have focused on the responses mediated by PPAR" modulated
by lysophosphatidic acids, especially in the vasculature; and we have introduced some of
the fundamental methods for examining the regulation of PPAR" by endogenous
lysophosphatidic acids analogs.
CPA is a high-affinity ligand and an endogenous negative regulator of PPAR",
unlike unsaturated acyl species of LPA and AGP, which have agonist properties (Figure
4-9).CPA binds to a site within the LBD, which inhibits PPAR" activation (Figure 4-9).
CPA binding to PPAR" facilitates conformational change that leads to recruitment of
corepressor SMRT, resulting in stabilization of the SMRT-PPAR" complex. LPA and
AGP induce neointima formation through the activation of PPAR", whereas, CPA
inhibits PPAR"-mediated arterial wall remodeling in the non-injury model. In addition,
the physiological stimulus of PLD2 is effective in PPAR"-dependent vascular
remodeling, and this effect is blocked by the PLD inhibitor FIPI in vivo. When
vehicle-treated CCAs were stained for CD133, no CD133-positive cells were observed;
however, CD133-positive cells were seen in the neointimal region when the artery was
treated with AGP. Moreover, the CD133-positive cells in the neointimal region also
expressed !SMA, suggesting that VPCs are recruited to form neointima in response to
AGP. There are some controversies about the contribution of VPCs (Daniel et al., 2010,
Iwata et al., 2010); therefore, further studies are needed to elucidate the role of LPA
GPCR and PPAR" in the regulation of VPCs.
These observations detailed in this present chapter were intended to point to the
intracellular signaling role of LPA and its analogs. Thus, LPAs fulfill dual roles as
mediators through the activation of cell surface GPCRs and as second messenger
intracellularly through the activation/inhibition of PPAR". Overall, our findings may
provide a novel mechanism for the regulation of PPAR" and they open novel therapeutic
opportunities. Further clarification of the PLD2-CPA axis could lead us to the possibility
of synthesizing novel medicines acting on PPAR".
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Figure 4-9

Schematic diagram of the PPAR! signaling

LPA, AGP, and ROSI activate PPAR" and promote downstream signals, whereas CPA
negatively regulates PPAR". CPA stabilizes PPAR"-SMRT corepressor complex and
inhibits PPAR"-mediated post signal transduction.
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APPENDIX.

SUPPLEMENTAL INFORMATION FOR CHAPTER 3
A.1

MATERIALS AND METHODS

A.1.1 Materials
Oleoyl cyclic phosphatidic acid (CPA 18:1) and 1-Ooctadecenyl cyclic glycerophosphate (CGP 18:1), oleoyl lysophosphatidic acid (LPA
18:1), 1-O-octadecenyl glycerophosphate (AGP 18:1), monooleoyl glycerol (MG), and
1-O-octadecenyl glycerol (AG) were purchased from Avanti Polar Lipids. CPA 18:1 was
repurified by thin layer chromatography (TLC) using
chloroform-methanol-ammonium hydroxide (3:6:1) on fluorescent indicator-free Silica
Gel 60 TLC plates (Whatman), and its purity was determined using negative ion liquid
chromatography- mass spectrometry (data not shown).
2-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoyl)-1hexadecanoyl-sn-glycero-3-phosphocholine (!-BODIPY FL C12-HPC) was obtained from
Invitrogen Japan. Rhizopus delemer lipase and phospholipase D from Actinomadura sp.
No. 362 were purchased from Seikagaku Co. (Tokyo, Japan). [32P]-AGP 18:1 was
synthesized from AG using purified recombinant 1,2-diacylglycerol kinase (Calbiochem).
Oleic acid (OA), 4#-phorbol 12-myristate 13-acetate (PMA), WY-14643, and L-165041
were purchased from Sigma. [3H]-ROSI (50 Ci/mmol) was purchased from American
Radiolabeled Chemicals, and cold ROSI, TRO and PIO from ALEXIS Biochemicals, Inc.
[32P]-Orthophosphoric acid (314-337 TBq/mmol) was purchased from PerkinElmer.
Mastoparan was from Bachem. Polyclonal anti-rabbit PPAR" antibody (H-100) was
purchased from Santa Cruz Biotechnology Inc. Polyclonal anti-rabbit FABP4 was
purchased from Cell Signaling Technology.
A.1.2 Plasmids and Vectors
SV40-!-galactosidase (Promega), pET15b (Novagen) and pcDNA3.1 (Invitrogen)
vectors were purchased. WT pcDNA3.1-PPAR"1 (amino acids 1-475) and
pET15b-PPAR"1-LBD (amino acids 173-475) were used as templates for mutagenesis as
described (Tsukahara et al., 2006). MH-100-PPRE-TK-Luciferase and
pCMX-PPAR"-Gal4 vectors were a gift from Dr. Peter Tontonoz (HHMI, UCLA, CA).
The construction and application of the pGL3b-PPRE-Luc, pGL3b-PPRE-cd36 plasmids,
the PPAR! and !/" reporter gene assays and PLD2 and CI-PLD2 bacmid vectors have
been previously described (Colley et al., 1997; Liliom et al., 2006). UAS-Luc,
pECE-Gal4-SMRT, and pVP16-PPAR"2 plasmids were a gift from Dr. Ron Cohen (U.
Chicago, IL).
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A.1.3 Synthesis Cellular Uptake and Visualization of BODIPY-CPA
N-((6-(2,4-dinitrophenyl) amino)hexanoyl)-2-(4,4-difluoro-5,7-dimethyl-4-bora3a,4a-diaza-s-indacene-3-pentanoyl)-1-hexadecanoyl-sn-glycero-3-phosphocholine
(BODIPY-PC) was deacylated by Rhizopus delemer lipase to prepare 2-BODIPY-labeled
LPC. 1-BODIPY-labeled LPC was generated through spontaneous acyl migration by
incubation at 37ºC for 3 h in 0.1 M TRIS-HCl buffer (pH 9.0). The 1-BODIPY-labeled
LPC was converted to BODIPY-CPA by transphosphatidylation using Actinomadura
phospholipase D as described previously (Tsuda et al., 2006). BODIPY-CPA was added
to a final concentration of 3 nmol/well to RAW264.7 cells (1.6106) and cells were
incubated for 0.5 to 60 min at 37°C. Cells were centrifuged and washed with ice-cold
PBS. The lipids from the cells and medium were separately extracted by the method of
Bligh and Dyer, and separated by TLC using
chloroform-methanol-acetic acid-1% sodium disulfite (100:40:12:5). Fluorescence
images of TLC plates were obtained and quantified with the FOTODYNE Image
Analysis system using the Analyst P 5.0 software (FOTODYNE Inc.). For microscopic
examination, RAW 264.7 cells were treated with 10 µM BODIPY-CPA and incubated at
37°C for 30 min. Cells were briefly rinsed with PBS and viewed with a NIKON Eclipse
80i fluorescence microscope.
A.1.4 Quantitative Determination of CPA by MS
MDA-MB-231 (3$107), 3T3-L1 or RAW 264.7 (3$106) cells per sample were
used in these experiments. Following serum starvation, cells were treated with 100 nM
PMA, 100 nM insulin (Sigma), or vehicle control (1% DMSO) for 30 min at 37°C and
washed with PBS and collected by centrifugation (Eppendorf centrifuge, 1,000 rpm, 2
min). Cellular phospholipids were spiked with 100 pmol of CPA 17:0 as internal standard
and extracted using chloroform/methanol (200/400 µl), and citrate-phosphate buffer, pH
4.0 (160 µl). Samples were extracted and analyzed by LC-MS as previously described
(Baker et al., 2001) with a Thermo-Finnigan LCQ Advantage mass spectrometer.
Quantification of the CPA species was done by ratioing the [M- H]- signal intensity for
CPA 16:0 and 18:1 to that of the signal intensity of CPA 17:0 internal standard.
LC-MS quantification of CPA in 3T3-L1 or RAW 264.7 cells (3.0$106)
expressing scrambled shRNA, PLD2 shRNA and WT were pretreated with 30 nM insulin
or 100 nM PMA for 30 min. Total lipid was extracted using Bligh & Dyer method with
100 pmol CPA 17:0 (m/z: 405.0) as internal standard and dissolved in 0.1 ml of
methanol/ chloroform/ 28% NH4OH (90:10:0.1) and were immediately analyzed by
electrospray ionization LC-MS. LC-MS was performed on an LCMS-2010A mass
spectrometer (Shimadzu, Japan) equipped with an Econosphere 3 µm 50 $ 4.6 mm silica
column (Alltech Associates, IL). The sample was maintained at 250°C with drying gas
flow of 1.5 L/min, and data were collected in the negative ion mode from 100 to 1000
m/z. The amount of CPA 18:1(m/z: 417.0) produced was estimated by the calibration
curve of CPA16:0 (m/z: 391.0) /17:0 (picomoles versus peak area). The final values are
shown with the standard errors for the three sets of experiments.
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Human PBMC were isolated from Leukopacks by Ficoll-Hystopaque density
gradient centrifugation. Monocytes were purified from human PBMC using MACS
CD14 microbeads (Miltenyi Biotech). Purity was checked by staining with a FITC
conjugated anti-CD14 antibody (Sigma) and FACScan analysis, and routinely found to be
higher than 94%. The cells (107) were pretreated with or without 750nM FIPI for 30 min
followed by treated with 1µg/ml lipoporysaccharide, 100nM PMA, 100nM insulin, or
1mM hydrogen peroxide for 30 min at 37°C. After the treatment the cells were washed
with PBS and collected by centrifugation. Total lipids were extracted as described above.
The samples were dissolved in 20 µl of chloroform/water/isopropanol/acetonitrile
(1:1:1:1) and CPA production was measured by LC- MS/MS. All LC-MS/MS analysis
was done with an Applied Biosystems Sciex (Foster City, CA) ABI 4000 QTRAP tandem
mass spectrometer equipped with a TurbolonsprayTM interface, a Shimadazu
LC-10ADvp pump (Columbia, MD) with a Leap HTS PAL autosampler (Carrboro, NC).
Ten microliters of each sample was injected to Tosoh TSK-ODS-100Z column (150mm
$ 2 mm; silica with 5-µm particle size) with methanol/water (95:5), 5mM ammonium
formate solvent with an isocratic flow rate of 0.22ml/min. The data was processed by
Analyst software, version 1.5. Various species of CPA were analyzed by multiple
reaction monitoring (MRM) in negative ion mode with Q3 (product ion) set at m/z 255.1
for CPA16:1, 281.1 for CPA 18:1, and 269.0 for CPA 17:0 (glycerophosphate moiety)
(Shan et al., 2008). Q1 was set for the deprotonated molecular ion for all
lysophospholipids. Quantification of CPA16:0 and CPA18:1 was done by taking the ratio
of peak area to that of CPA 17:0 internal standard.
A.1.5 PLD2 Knockdown
The lentiviral vector pLKO1(clone ID#: TRCN0000076937) containing the
validated PLD2 shRNA sequence CCGGGCAGTGTTTCCGAGTCTACTTCTCGAGA
AGTAGACTCGGAAACACTGCTTTTTG was purchased from OpenBiosystems
(Huntsville, AL.USA). The scrambled shRNA plasmid (#1864) was obtained from
Addgene (Cambridge, MA, USA), in which a nonsilencing sequence CCGGCCTAAGGT
TAAGTCGCCCTCGCTCTAGCGAGGGCGACTTAACCTTAGGTTTTTG was
inserted into lentiviral vector pLKO1. The lentiviruses with scrambled and PLD2 shRNA
were produced in UTHSC Viral Vector Core Laboratory (Memphis, TN, USA). Briefly,
the shRNAs in pLKO1 were co-transfected into 293FT cells with the packaging plasmids
pCMV-VSVG and psPAX2. The supernatant was collected 60 h after transfection and
virus particles were collected by ultra-centrifugation. 3T3-L1 and RAW 264.7 cells were
transduced by the viruses at 10 MOI. 3T3-L1 and RAW 264.7 stably expressing
lenti-mediated shRNA for PLD2 were grown in DMEM containing 10% FBS and
puromycin (Sigma) (2.0 µg/ml for 3T3-L1, 3.0 µg/ml for RAW 264.7). The knockdown
of PLD2 shRNA was examined by immunoblotting using an antibody specific to PLD2
(gift from Dr. Yoshiko Banno, Gifu University, Japan). RAW264.7 or NIH3T3 cells
expressing scrambled shRNA (SC-shRNA) or PLD2 shRNA (PLD2-shRNA) were lysed,
the lysates were separated by SDS-PAGE and transferred to a PVDF membrane. The blot
was probed with the anti-rabbit anti-PLD2 antibody (1:2000), and incubated with
anti-rabbit secondary antibody conjugated to horseradish peroxidase (Promega, Madison,
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WI; 1:10000) and visualized using SuperSignal ELISA Pico substrate (Thermo Fisher
Scientific Inc., Rockford, IL).
A.1.6 Purification of Recombinant PLD2
Sf-9 insect cells were transduced with recombinant baculoviruses encoding PLD2
or CI-PLD2 at MOI of 10. The cells were grown for 48 h and washed with PBS, lysed on
ice by the addition of 3 ml lysis buffer [20 mM TRIS-HCl, pH7.4, 100 mM NaCl, 0.5%
Triton X-100, 1 mM PMSF and protease inhibitor cocktail (Sigma)]. After 15 min on ice,
the cells were collected by scraping and the lysate was centrifuged at 13,000$g for 30
min at 4°C. The supernatant was mixed with 0.1 ml TALON His-tag Affinity Resin (BD
Biosciences) and kept at 4°C with constant agitation for 1 h. PLD2 was eluted after the
resin was washed three times with 1 ml of lysis buffer. The purity of the PLD2
preparation was tested by western blotting with a mouse anti-polyhistidine antibody
(Sigma) or a rabbit anti-actin (Sigma) primary antibodies, and an anti-mouse or
anti-rabbit IgG horseradish peroxidase conjugated secondary antibody (Promega),
visualized using the Super Signal kit (Pierce).
A.1.7 In Vitro Assay of PLD Activity
Purified PLD2 was incubated with 50 µM [14C]-LPC 16:0 (2.1 GBq/mmol) at
40°C for 1 h in the presence of 10 mM TRIS-HCl, (pH7.2). The reaction was terminated
by 30 µl 1-BuOH. The mixture was centrifuged at 12,000$g for 1 min and the upper
phase was spotted on Silica Gel 60 TLC plates (Whatman). The plates were developed
with chloroform/methanol/acetic acid/1% aqueous sodium metabisulfite (100:40:12:5).
Radioactivity was detected using a Cyclone phosphorimager. PLD activity in cell lysates
was determined using the Amplex Red PLD kit from Molecular Probes (Eugene, OR).
A.1.8 Oil Red O Stain
RAW 264.7 cells were seeded in Lab-Tek slide-chambers in DMEM at 104 cells
per well for 24 h. Acetylated LDL (25 µg/ml) was added. After 24 h, the cells were
washed twice with PBS and fixed with 10% formaldehyde in PBS for 10 min. ORO
(0.5%) in isopropanol was diluted with 1.5 volumes of distilled water, filtered, and added
to the fixed cells for 1 h. Cells were viewed using a Nikon Eclipse 80i microscope.
3T3-L1-derived adipocytes were washed three times with PBS and fixed for 2 min with
10% formaldehyde in PBS. Cells were then washed three-times with wash solution
(Chemicon International) and stained with ORO. For the quantification of ORO uptake,
cells were extracted using dye extraction solution (Chemicon International), and
absorbance was measured at 520 nm in a Shimadzu UV-1700 spectrophotometer.
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A.1.9 Induction of Adipocytic Differentiation in 3T3-L1 Cells
Cells were cultured in DMEM supplemented with 10% FBS to reach confluence.
1 µM CPA or vehicle (1% DMSO) was added 24 h prior to induction with 100 nM ROSI
with 0.1 - 10 nM insulin. The medium with ligand(s) was replenished every other day.
Cytoplasmic lipid droplets were visible by day 5. The cells were cultured following the
standard differentiation induction protocol for 14 days. Adipogenesis was determined by
staining of lipids with ORO and by RT-PCR and western blotting for the expression of
adipocyte marker FABP4.
A.1.10 Animal Experiments
The procedure used in these experiments was approved by the IACUC of the
University of Tennessee Health Science Center. The surgical procedure for exposing and
cannulating the external and common carotid arteries has been described previously
(Zhang et al., 2004). Briefly, 5 µM ROSI or AGP with and without 5 µM CPA or 3 nM
insulin were injected into a ligated carotid artery previously rinsed free of blood; the
cannula was left in the vessel for 1 h. The cannula was then withdrawn and the external
carotid was ligated. The clips isolating the distal and proximal common carotid were
released, and blood flow was restored. All animals (groups of 5 for each treatment)
received adequate analgesia and preventive antibiotics during recovery. Three weeks post
surgery the animals were euthanized, and the carotid arteries were dissected en-block,
fixed, and processed for paraffin embedding. Sections 5 µm thick were cut and stained
using Masson’s trichrome stain (Richard-Allan Scientific Inc.). Intima-to-media ratios
were measured using the NIH Image (version 1.62) software.
A.1.11 RNA Extraction and Real-Time Quantitative RT-PCR
C57BL/6 mouse peritoneal macrophages were pretreated with 5 µM CPA or 1µM
GW9662 for 15 min and cultured for 12 h in the presence of 5 µM ROSI. 3T3-L1 and
RAW 264.7 cells were treated with 30nM insulin or 10µM mastoparan for 30 min
followed by treated with vehicle or 10µM ROSI for 24h. RNA was isolated by using
TRIzol-LS (Invitrogen) and quantitative real-time RT-PCR analysis was performed using
7300 Fast Real-time PCR system, (Applied Biosystems). Transcript levels were
normalized to !-actin or GAPDH for 3T3-L1 and RAW 264.7 cells. Experiments were
done using four different pools of macrophages collected from 10 mice. RNA from
3T3-L1 cells was isolated using RNAspin Mini kit (GE Healthcare). Assays of reverse
transcription were conducted with specific primer for PPAR", FABP4 and !-actin and 1
µg of total RNA in 25 µl reaction volume. Reverse transcription was performed at 50 °C
for 60 min and the PCR conditions were as follows: 94 °C for 30 s, 50 °C for 60 s, and 72
°C for 60 s with initial activation of enzyme at 94 °C for 1 min for a total of 35 cycles.
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A.1.12 PCR Primers Used
qPCR; cd36; forward GCCTCCTTTCCACCTTTTGT, reverse TCTGTACACGG
GGATTCCTT, cyp27a1; forward GGCACCTTTCCTGAGCTG, reverse CACCAGTCA
CTTCCTTGTGC, hadh; forward GACATCCTGGCAAAATCCAA reverse GCTCAGG
GTCTTCTCCACAA, capn3; forward TACGCAGGGATCTTCCACTT, reverse GAAC
TCATTGCGGTGGTTG, csf1; forward GAGTCTGTCTTCCACCTGCTG, reverse ACT
GGCAGTTCCACCTGTCT, ppar$; forward AGGGCGATCTTGACAGGAA, reverse C
ACCTCTTTGCTCTGCTCCT, #-actin; forward TTCTACAATGAGCTGCGTGTG
reverse GGGGTGTTGAAGGTCTCAAA, pld1; forvard AGTGCTTCAGACTTGTCCT
GGTT, reverse ATGGTAGCGTTTCGAGCTGCTGT, pld2; forward TTGCGGAAGCA
CTGTTTCAGTGTG, reverse TTGTTCTCCGCTGTTTCTTGCCAC.
RT- PCR; #-actin; forward GACAACGGCTCCGGCATGTG reverse GGCTGG
GGTGTTGAAGGTCTCAA, fabp4; forward AATGTGTGATGCCTTTGTGGG reverse
TGGCTCATGCCCTTTCA.
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Figure A-1 Inhibition of Pioglitazone (PIO) and Troglitazone (TRO)-induced
reporter gene activation by CPA (related to Figure 3-1)
(A and B) CPA dose-dependently suppresses PIO or TRO-induced PPAR"-dependent
PPRE-TK- Luc reporter gene activation in B103 cells. The cells were treated for 20 h
with ligands and/or different concentrations of CPA as indicated (n=4). Data are
representative of two independent transfections. (C-F) CPA does not activate PPAR# and
PPAR!/&. CPA did not activate PPAR# and !/& reporter gene expression over a
wide-range of concentrations in B103 cells exposed to WY-14643 (C, PPAR#-specific
agonist) or L-165041 (E, PPAR!/&-selective agonist) or CPA 18:1 for 20 h. No reporter
gene activation was found after treatment with up to 10 µM of CPA, the highest
concentration tested, whereas nanomolar concentrations of the synthetic agonists elicited
robust expression of the reporter genes. CPA did not inhibit specific agonist induced
PPAR# or PPAR!/& activation (D and F).
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Figure A-2

PLD2 induces CPA production (related to Figure 3-4)

(A) PMA-induced CPA generation in CHO cells transfected with tet-regulated PLD1 and
PLD2 constructs without doxycycline induction. 106 Cells biosynthetically labeled with
[32P]-orthophosphate were treated with 100 nM PMA for 30 min, and CPA was isolated
and separated using 2DTLC and quantified by liquid scintillation counting (n=3). (B)
Enzymatic properties of PLD2 using LPC as substrate. Affinity-purified recombinant
PLD2 and CI-PLD2 were reacted [14C]-LPC (2.05 GBq/mmol) in vitro, and generation of
[14C]-CPA was quantified using a [14C]-sensitive phosphorimager screen. The Vmax and
Km values were derived from double-reciprocal plots of the data (insets) yielding
Vmax=190 pmol/min/mg protein, Km =20 µM for LPC, Data represent the mean ± SEM
of values from three experiments. (C-E) Mass spectrometry of CPA production in
MDA-MB-231 cells. Cells (3$107) were treated with DMSO (vehicle), PMA (100 nM),
or insulin (100 nM) for 30 min, spiked with 100 pmol of CPA 17:0 (m/z 405), and CPA
was extracted. In vehicle-treated cells (C) CPA was below the detection limit (>10
pmol/3$107 cells). In contrast, significant amounts of CPA 16:0 (m/z 391) and CPA 18:1
(m/z 417) were readily detected in PMA- (D) and insulin-treated cells (E). LC- MS/MS
quantification of CPA species in unstimulated (F), and insulin (100 nM, G), or PMA (100
nM, I) stimulated human peripheral blood monocytes. The cells were treated for 30 min
with the activators and in some cases also pretreated with 750 nM of the PLD2 inhibitor
FIPI (H). CPA were analyzed by MRM in negative ion mode monitoring the
glycerophosphate moiety at m/z 255.1 for CPA16:1, 281.1 for CPA 18:1, and 269.0 for
CPA 17:0 (internal standard). CPA was below the detection limit in unstimulated cells
but became detectable after insulin or PMA stimulation. FIPI reduced CPA production.
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Figure A-3 Insulin induced CPA production and PLD2 knock down by shRNA
(related to Figure 3-5)
(A-C) Stimulus coupled CPA production in CV-1 cells. Cells (3$106) were labeled with
[32P]-orthophosphate for 6 h, subsequently exposed to 100 nM insulin or 1% DMSO
solvent for 30 min at 37°C, and lipids were extracted and analyzed by 2DTLC and
phosphorimaging. (A) [32P]-labeled phospholipids in DMSO treated cells. (B) Primulin
staining of the plate shown in panel A spiked with authentic LPA and CPA standards (10
nmols each; A-C designate unidentified phospholipids). (C) [32P]-labeled phospholipids
in cells treated with 100 nM insulin. Arrows point to spots co-migrating with the CPA
and LPA standard. Note that there in no increase in LPA upon insulin stimulation and as
a metabolite of phospholipids synthesis LPA shows a constitutive turnover indicated by
the incorporation of the label. In contrast, CPA shows a robust increase upon insulin
stimulation. (D and E) shRNA knockdown of PLD2 in RAW 264.7 (D) and 3T3-L1 cells
(E). Quantitative RT- PCR showed a selective decrease in pld2 transcripts without
significant change in pld1 transcript abundance. (F) Western blotting of PLD2 protein
shows diminished levels in the PLD2-shRNA transduced cells compared to WT or
scramble shRNA transduced cells.
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Figure A-4 CPA and insulin prevent ROSI-induced carotid wall remodeling
(related to Figure 3-7)
CPA and insulin inhibit neointima formation induced by ROSI in rat carotid arteries.
(A-D) Carotid arteries of anesthetized adult female rats were cannulated and filled with 5
µM ROSI either with or without 5 µM CPA for 1 h; after this treatment, the circulation
was restored. Animals were sacrificed 3 weeks later, and the carotid tissue was processed
for Masson trichrome staining. (A) In carotids arteries treated with 3% DMSO PBS
vehicle no changes in vascular wall morphology were noted. The PPAR" agonist
ROSI-induced neointima formation (B) in the common carotid arteries was blocked by
co-application of CPA (C, bar, 200 µm). Intima-to-media ratios were determined in the
carotids using quantitative image analysis (D). CPA completely abolished ROSI-induced
neointima formation. Data represent the mean intima- to-media ratio ± SD of carotid
arteries from groups of 5 rats. (E-G) Insulin (3 nM, E) was co-applied with 10 µM ROSI
(F) lumenally for 1 h using the described experimental paradigm. Insulin treatment alone
induced no vascular remodeling, but it significantly reduced the neointima formation
elicited by ROSI. Bar; 200 µm. (G) Data represent the mean intima-to-media ratio ± SD
for groups of 5 carotid arteries.
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